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Malaria remains a leading cause of morbidity and mortality in tropical regions of the world 
despite the numerous global efforts to control and manage the disease through prevention and 
drug intervention. An estimated 300–500 million people are affected by malaria each year, 
resulting in 1.5–2.7 million mortalities annually. Recent reports indicate that 90% of malaria-
related deaths occur in the Sub-Saharan Africa, where a child under five years of age dies 
every 30 seconds.  The development of immunity and increasing resistance to affordable 
antimalarial drugs is believed to be one of the factors that have led to the increasing number 
of malaria cases. As a result, the WHO has recommended the use of artemisinin combination 
therapies (ACTs) for management of malaria.  However, these have proven to be very costly 
and inaccessible in many low-income countries.  Therefore, CHQ has remained the mainstay 
therapy for malaria prophylaxis and treatment despite development of Plasmodium 
falciparum resistance to this drug. The decrease in CHQ efficacy is attributed to a number of 
factors which are associated with the conventional oral route of administration. CHQ has a 
bitter, unpalatable taste when administered orally which, more often than not lead to patient’s 
non-compliance. This is thought to be one of the factors that have led to the increasing 
number of CHQ resistant strains of P. falciparum.  Moreover, when administered orally, 
CHQ is reported to deposit in epithelial cells of many vital organs including the liver, heart 
and kidneys where the drug elicits adverse effects on physiological functions. Hypoglycaemia 
and impaired renal fluid and electrolyte handling are some of the adverse effects associated 
with oral administration of CHQ. The present study was designed to develop a novel CHQ-
formulation that delivers sustained slow CHQ release into the systemic circulation. We also 
investigated the ability of this CHQ formulation to clear the malaria parasites in Plasmodium 
berghei-infected male Sprague-Dawley rats. The other objective of the study was to 
investigate and distinguish between the patho-physiological effects of malaria parasites and 
CHQ treatment on blood glucose homeostasis and renal fluid and electrolyte handling in rats.  
 
 
The studies were carried out over a period of 3 weeks, divided into pre-treatment (days 0-7), 
treatment (days 8-12) and post treatment (days 13-21) periods. To distinguish between the 
effects of CHQ treatment and malaria infection on blood glucose homeostasis and renal 
function, separate groups of non-infected and P. berghei-infected male Sprague Dawley rats 
(90g-150g) were used. The animals were housed individually in Makrolon polycarbonate 




CHQ (30 mg), twice daily, 8 hours apart or a once off topical application of the pectin-CHQ 
matrix patch (56 mg). To evaluate the ability of our novel CHQ-formulation to clear the 
malaria parasites, pectin-CHQ matrix patches containing 28 and 56 mg of CHQ were used. 
These doses were calculated based on current clinical doses for the treatment of malaria. 
However, to assess the short-term effects of our CHQ formulation, a pectin-CHQ patch 
containing 56 mg CHQ was used. This dose was chosen based on preliminary studies.  
Percentage  parasitaemia,  mean body weight changes, food and water intake, mean arterial 







were monitored every third day during the pre-treatment and post-
treatment periods. However, during the treatment period, all these parameters were monitored 
daily. To assess the effects of CHQ treatments on some biochemical parameters such as  
plasma CHQ profiles, electrolytes, AVP and insulin concentrations, separate groups of 
animals (n=6) were sacrificed during pre-treatment at days 0 and 7, treatment period at days 
8, 9, 11, 12 and post-treatment period at day 21. 
 
The results indicate that we were able develop a novel CHQ-formulation and achieved drug 
percentage incorporations ranging between 52-74%. Furthermore, the amounts of CHQ 
obtained in the patch compare to clinical doses. We have also demonstrated the ability of the 
pectin-CHQ matrix patch formulation to deliver sustained controlled therapeutic doses of 
CHQ which cleared the malaria parasites within a period of 5 days. Oral administration of 
CHQ significantly decreased blood glucose concentrations of non-infected and P. berghei 
infected rats with a concomitant increase in plasma insulin concentration.  Animals treated 
with a once off- topical application of the pectin-CHQ matrix patch presented with blood 
glucose concentrations which were comparable to those of untreated non-infected control 
animals. Both malaria infection and oral CHQ treatment significantly reduced food intake, 
water intake and % body weight changes by comparison with untreated non-infected control 





which were mediated through increased plasma AVP concentrations and red blood cells 
haemolysis respectively. The P. berghei parasites and oral CHQ treatment demonstrated 
blood pressure lowering effects without any change in GFR. On the other hand the once off 










The current study has demonstrated that the pectin-CHQ matrix patch formulation not only 
clears the malaria parasites from the systemic circulation, but sustains normal blood glucose 
concentrations and does not affect renal function of malaria infected animals. This suggests 
that transdermal CHQ delivery has the potential to ameliorate the pathophysiological effects 
that are associated with oral CHQ treatment and could provide an alternative method for the 








 Malaria  is a large cause of morbidity and mortality worldwide (Tuteja, 2007). According to 
the World Health Organization (WHO), malaria is responsible for approximately 660 000 
deaths, with  Sub-Saharan Africa being the most affected (WHO, 2013). Recent reports 
indicate that 90% of malaria-related deaths occur in  Sub-Saharan Africa (WHO, 2013), 
where a child under five years of age dies every 30 seconds (WHO, 2000). This infectious 
disease remains a major health and socioeconomic problem in many low-income countries. In 
recent years, the burden of the disease and mortality has increased significantly and 
transmission has spread to new areas (le Sueur et al., 1996). The major cause of this 
increased mortality and transmission rates is the development of resistance to affordable 
chemotherapies (Greenwood & Mutabingwa, 2002) and insecticides (Hemingway et al., 
2002). Novel approaches that might improve the efficacy of the already existing antimalarial 
drugs are needed. 
 
 Malaria is caused by protozoan parasites of the Plasmodium genus. There are four species  
which cause human malaria, but Plasmodium falciparum (P. falciparum) causes nearly all the 
deaths and malaria associated complications (Tuteja, 2007). Chloroquine, a 4-aminoquinoline 
has and is still used widely for both treatment and prophylaxis of malaria. Due to the 
increasing number of CHQ resistant P. falciparum strains, the WHO has recommended the 
use of artemisinin combination therapies (ACTs) such as artesunate-amodiaquine, 
artemether-lumifantrine and artesunate-mefloquine. However, these have proven to be very 
costly and inaccessible to many developing countries. Hence, CHQ remains the primary drug 
for the treatment and prophylaxis in some malaria endemic areas, including Sub-Saharan 
Africa.  Chloroquine has been reported to elicit adverse effects on blood glucose homeostasis 
following oral administration (White et al., 1983). In addition, current research has shown 
that oral CHQ also evokes adverse effects on renal electrolyte handling (Musabayane et al., 
1993). CHQ has been reported to cause cardiac nerve impulse conduction disturbances 
(Sanguinetti & Jurkiewicz, 1990, Shah, 2005, Owens & Nolin, 2006) and hypotension 
(Looareesuwan et al., 1986). All these adverse complications are believed to be partly 




and/or malaria parasites. Some studies have recorded peak plasma CHQ concentrations 
ranging between 65 and 263 ng/ml following single oral dose of 10 mg/kg (Walker et al., 
1983). CHQ has a long half-life (1-3 months) and a slow elimination rate (Gustafsson et al., 
1983). The drug is deposited in tissues such as the heart, kidney and liver, where is disrupts 
physiological functions such as glucose homeostasis and renal functions. Hence, there is a 
need for the search of alternative CHQ delivery systems. These systems must try and avoid 
the use of high drug concentrations, and therefore evade the accumulation of CHQ in tissues. 
Transdermal drug delivery has been reported to provide a sustained controlled release of 
drugs directly into the systemic circulation (Prausnitz & Langer, 2008). In addition, we have 
observed that transdermal administration of CHQ via the pectin CHQ-matrix patch 
formulation sustains controlled release of CHQ into the bloodstream in non-infected 
experimental animals (Musabayane et al., 2003).  Hence the present study investigated the 
efficacy of transdermal delivery of CHQ via the pectin CHQ-matrix patch on Plasmodium 
berghei infected rats. We also evaluated the short-term effects of this novel CHQ formulation 
on blood glucose concentration and renal electrolyte handling in malaria infected rats. 
 
1.2. The Plasmodium life cycle  
The Plasmodium species exhibits a complex life cycle requiring a vector and a vertebrate host 
(Figure 1). The infection is initiated when sporozoites are injected into the host’s bloodstream 
by a feeding female Anopheles mosquito (Tuteja, 2007). These sporozoites quickly migrate to 
the liver where they invade hepatic cells. Within the hepatic cells, the sporozoites undergo 
asexual reproduction referred to as exoerythrocytic schizogony. This asexual stage results in 
the production of merozoites, which are then released into the circulatory system, where they 
infect red blood cells (RBCs) and undergo further multiplication and differentiation, a 
phenomenon referred to as trophic period, producing trophozoites. The enlargement of these 
trophozoites results into the production of schizonts (Tuteja, 2007). The erythrocytic stage of 
the Plasmodium life cycle is responsible for most malaria associated pathologies including 
fever and anaemia. CHQ, the drug of choice in the current study exerts anti-malarial activity 
by targeting this erythrocytic stage of the life cycle. The destruction of RBCs by the parasite 
is responsible for the reported malaria-associated anaemia. However, it is unclear whether 





The shizonts that are produced from the erythrocytic stage of the life cycle either further 
infect more red blood cells or differentiate into sexual forms, macro- or microgametocyte. 
Ingestion of these microgametoctes by the next feeding Anophele mosquito triggers 
gametogenesis (Tuteja, 2007, Wells et al., 2009 ). The sexual cycle in the vector is completed 
by differentiation of some merozoites into male and female gametocytes which subsequently 
develop into sporozoites (Clark & Schofield, 2000, Mackintosh et al., 2004). The cycle is 
initiated again when these sporozoites are introduced into the next vertebrate host.  Figure 1 









The increase RBC destruction by the Plasmodium parasite is thought to play a major role in 
the development of anaemia. However, the destruction of RBCs alone is not adequate to 
explain the severe anaemia that is reported in malaria patients receiving oral CHQ treatment. 
Hence, the current study will investigate the possible mechanism for the reported anaemia.  
 
Anaemia is one of the most severe malaria complications and accounts for a significant 
number of malaria related mortality. The pathophysiology that is associated with this 
complication is not clearly understood. However, some studies have reported the involvement 
of both intravascular and extravascular destruction of parasitized and unparasitized RBCs  as 
well as a reduced erythropoiesis (Bjo¨rkman, 2002). In chronic anaemia hypersplenism and 
dyserthropoiesis are believed to be the main factors causing anaemia, whereas in acute 
anaemia intravascular is the focal factor (Abdalla et al., 1980). In malaria infection, there is a 
high rate of RBC destruction by the parasites without any parallel replacement by 
erythropoiesis. This destruction is mediate through multiple mechanisms including the 
rupture of RBC, phagocytosis of parasitized and unparasitized RBCs and hypersplenism. 
During its life cycle, the Plasmodium parasite invades RBCs where replication occurs, 
resulting into the rupturing of RBCs to release schizonts, resulting to the reduction of RBCs 
(Phillips et al., 1986, Phillips & Pasvol, 1992 ). The proliferation and hyperactivity of 
macrophages within the reticuloendothelial system in response to the destruction of RBCs is 
responsible for the phagocytosis of both parasitized and unparasitized RBCs. This removal of 
unparasitized RBCs is believed to be one of the mechanisms resulting into persistent anaemia 
(Phillips & Pasvol, 1992 , Slutsker et al., 1994). Splenic hypertrophy and hypersplenism also 
contribute to the destruction of RBCs during malaria infection. The spleen plays a pivotal 
role in the clearance of the Plasmodium parasites by filtering parasitized RBCs from the 
circulation, hence contributing to the early anaemia associated with acute malaria (Angus et 
al., 1997).  
 
1.2.1. Role of hepcidin in anaemia 
 
Recent evidence suggests that the above mentioned mechanisms alone or in combination do 
not adequately explain the anaemia of malaria infection (McDevitt et al., 2004). Hepcidin, a 
recently discovered peptide hormone, is a major regulator of iron metabolism and is thought 




The presence of the malaria parasite triggers the host’s innate immune system. Also, the 
release of toxins during the Plasmodium parasite’s life cycle triggers the release of the pro-
inflammatory cytokines, TNF-α, IL-6 and IL-22. Together with type I interferon, these 
cytokines stimulate hepcidin transcription through STAT3 signalling (Howard et al., 2007). 
This hepcidin then blocks the release of iron from enterocytes, hepatocytes, and 
macrophages, leading to hypoferremia and limited iron availability for erythropoiesis 
(McDevitt et al., 2004). Some studies have suggested that the quinolone ring of CHQ and 
other quinine related drugs may act as a hapten, and binds with specific RBC proteins to elicit 
an immune response leading to the destruction of red blood cells, thus aggravating anaemia 
(Clark & Cowden, 2003). In summary, the exact cause of anaemia in CHQ treated malaria 
patients still remains unclear. Therefore, there is need to investigate and distinguish between 
the pathophysiological effects of malaria alone and those of CHQ treatment on parameters 
such as haematocrit. Haematocrit is the volume percentage of red blood cells in the blood and 
gives an integral part of the complete blood count. The current study will, therefore, 
investigate and compare the effects of malaria infection and that of treatment on haematocrit 
levels in an effort to establish the possible mechanism for the reported malaria associated 
anaemia.   
 
1.3. Management of malaria 
1.3.1. Control of malaria transmission 
 
Vector control is one of the most effective methods used to reduce the transmission of 
malaria at the community level (WHO, 2013). Two forms of vector control, indoor residual 
spraying (IRS) and long-lasting insecticide-treated nets (LLINs) have been shown to reduce 
malaria transmission when used against insecticide susceptible mosquito populations. IRS 
and LLINs reduce the Anopheles mosquito’s daily survival rate and human biting frequency. 
However, mosquito resistance to pyrethroids, has been reported in some malaria endemic 
areas, including Sub-Saharan Africa. This increasing resistance of Anopheles mosquitos to 
pyrethroids has resulted in an increase in malaria related morbidity and mortality rates 
(WHO, 2013). The increasing number of pyrethroids resistant Anopheles mosquitos has led to 
the increased use of self-administration antimalarial drugs for the treatment and prophylaxis 
of malaria. The use of these antimalarial drug has resulted in a significant reduction in 
malaria related morbidity and mortality rates in many tropics including India and  Sub-




that are used for the management of malaria including CHQ which will be used in the current 
study for transdermal application.  
 
1.3.2 Drug intervention for the management of malaria  
 
Chemotherapy remains the most effective intervention for the reduction of malaria associated 
mortality and morbidity rates. The increasing resistance of P.falciparum to a number of anti-
malarial drugs   poses a great challenge in the management of malaria.  There are many 
standard anti-malaria drugs which have been put in place for the management of malaria; 
including artermisinin derivatives, antifolates and quinine related drugs which can be used as 
monotherapy or in combination for the treatment of malaria. The following sections discuss 
the various anti- malarial drugs as well as their mechanisms of action. More often than not, 
these drugs are associated with inconvenient dosing schedules which lead to patient non-
compliance. This patient non-compliance is believed to be one of the factors contributing to 
the increased number of resistant Plasmodium strains. The current study will investigate 
transdermal drug delivery as an alternative CHQ administration to try and eliminate the 
inconvenient dosing schedule that is associated with oral CHQ administration. 
 
1.3.2.1 Artemisinin derivatives 
 
Artemisinin also known as qinghaosu; is a natural component isolated from Artemisia annua.  
The plant Artemisia annua has been used since ancient times by the Chinese community as a 
traditional remedy for the treatment of fever. It was not until the early 1970s that the active 
ingredient, artemisinin, was isolated and the anti-malaria activity of this plant extract against 
P. falciparum demonstrated. A number of artemisinin derivatives have been synthesized and 
shown to be potent against P. falciparum (Meshnick et al., 1996, Meshnick, 2002). Some of 
these derivatives include artemether, arteether, artesunate and artenimol. The success of 
artemisinin derived anti-malarial drugs is ascribed to the reactivity of the endoperoxide 
bridge; a structural feature that is common in all artemisinin derived anti-malarial drugs. The 
novel structure and mode of action of these artemisinin derivatives has resulted to a reduction 
in malaria related mortality and morbidity rates (Meshnick et al., 1996). One of the problems  
with the use of  artemisinin drugs is that when used as monotherapies  over short periods , the 
clearance of the malaria parasites from the blood is only temporary in up to 50% of patients 




these artemisinin drugs from the body. Hence artemisinin drugs are now used in combination 
with other antimalarial drugs which have slow elimination rates, such as mefloquine. The 
combination of a high dose of mefloquine at the end of a full course of artemisinin drug 
treatment has been shown to produce  higher cure rates (Looareesuwan et al., 1994). In 
addition, due to the increasing reports of  artemisinin resistance strains of P. falciparum; the 
WHO has  recommended the use of artemisinin derivatives as combination therapies (ACTs) 
(WHO, 2003). Some of the commonly used ACTs include artesunate-amodiaquine, 
artemether-lumifantrine and artesunate-mefloquine. Even though these ACTs have shown 
potency against resistant P. falciparum, they are however inaccessible to developing 
countries due to high cost. An estimate of 48.4 million dollars has been spent for the 
implementation of ACT worldwide. As a result, quinine drugs such as CHQ remain the 
mainstay therapy in many African countries.  
 
1.3.2.2 Quinine related drugs 
 
Quinine, extracted from Cinchona bark, has provided the basis for the development of 
synthetic quinoline-containing antimalarial drugs such as chloroquine (CHQ), primaquine 
and mefloquine. Quinine is a basic,  cinchona alkaloid that belonging to the arylamino 
alcohol group of drugs (Achan et al., 2011). The exact mechanism by which this anti-malarial 
drug exerts therapeutic effects remains unclear. Quinine has rapid schizonticidal properties 
against intra-erythrocytic malaria parasites. This antimalarial drug also possesses 
gametocytocidal properties against P. vivax and P. malariae (Achan et al., 2011) but has no 
effects against P. falciparum. According to the WHO, quinine has a low therapeutic index 
and is associated with multiple adverse effects (WHO, 2000), including abdominal pain, 
diarrhoea, and also loss of vision (Achan et al., 2011) which has resulted to the limited use of 
this anti-malarial drug. Primaquine is an 8-aminoquinoline with schizonticidal activity 
against pre-erythrocytic liver latent tissue forms of P. vivax and P. ovale (Fernando et al., 
2011). Primaquine is rapidly absorbed in the gastrointestinal tract and peaks in plasma within 
1-3 hours following administration. This drug has a short plasma half-life of 4-9 hours and is 
rapidly  excreted in urine (Fernando et al., 2011).  Previous studies have shown that 
primaquine elicits adverse haemolytic effects in glucose-6-phosphate dehydrogenase (G6PD) 
deficient patients including pregnant women (Amos et al., 2010, Fernando et al., 2011). In 
addition, the inability of this drug to confer protection against asexual blood stages of P. 




Hoffman, 2004). As a result CHQ has remained a mainstay therapy in some areas. However 
the traditional mode of administration, oral, is associated with transiently high plasma CHQ 
concentrations which in turn elicit adverse effects on blood glucose homeostasis and renal 
functions. Transdermal drug delivery of CHQ will be investigated as an alternative CHQ 
administration method. The next sections briefly discuss CHQ, looking at its mechanism of 
action as well as its effects on blood glucose and renal electrolytes handling.  
 
1.4 Chloroquine (CHQ) 
 
CHQ phosphate is a 4-aminoquinoline antimalarial drug that has shizonticidal properties. 
This antimalarial drug was ignored for a decade and was considered to be too toxic for human 
use. However, during the early 90s clinical trials for anti-malarial drugs development were 
carried out and showed unequivocally that CHQ has a significant therapeutic value as an anti-
malarial drug. In 1947, CHQ was introduced into clinical practice for the prophylactic 
treatment of malaria. The great success of this drug is believed to be attributed to its 
mechanism of action.  
 
1.4.2 Mechanism of action of chloroquine 
CHQ’s efficacy is speculated to lie in this drug’s ability to interrupt the detoxification of 
haematin in malaria parasites as they grow within their host’s red blood cells. Haematin is 
released in large amounts as the parasite consumes and digests haemoglobin within the 
digestive food vacuoles (Zhang et al., 1999). Haematin is highly toxic to the malaria parasite 
and is normally detoxified by polymerization into innocuous crystals of haemozoin pigment 
and perhaps also by a glutathione-mediated process (Zhang et al., 1999, Wellems & Plowe, 
2001). CHQ exerts antimalarial activity by interfering with the process of haematin 
detoxification. This 4-aminoquinoline binds with haematin in its µ- oxodimer form and 
adsorbs to the growing faces of the hemozoin crystals disrupting the detoxification process, 
thus poisoning the parasite (Zhang et al., 1999). The result is the generation of toxic CHQ-
haeme complexes as well as accumulation of free haem moieties within the parasite’s food 
vacuole. The accumulation of these moieties results in RBC lysis, eventually killing the 





The reasonable cost and rapid onset of action of CHQ has resulted to the continuous use of 
this drug despite of the reported resistance. However, over the years CHQ use has decline due 
to a growing number of CHQ-resistant strains of P. falciparum. The decrease in the CHQ 
efficacy is thought to be attributed to a number of factors which are associated with the 
conventional route of administration (Musabayane et al., 2003). The conventional route of 
CHQ administration involves oral administration of tablets. This oral dosing schedule 
involves the administration of 4 tablets (with 250mg of chloroquine diphosphate in each 
tablet) upon presentation of the disease, 2 tablets taken 6 – 8 hours later, and then 2 tablets 
per day for the succeeding 2 days, adding up to a total of 2500mg of chloroquine 
diphosphate. Patient noncompliance  during CHQ treatment is one of the factors that is 
thought to cause therapeutic failure of this drug (Musabayane et al., 2003). This patient non-
compliance often results in incomplete treatments, which is believed to have led to the 
growing number of CHQ-resistant strains of P.  falciparum in  Sub-Saharan Africa (White, 
2004). In addition, when administered orally, CHQ is susceptible to gastrointestinal 
degradation as well as first-pass metabolism by the liver; as a result high initial CHQ 
concentrations are required to bring therapeutic effects. The use of high CHQ concentrations 
leads to accumulation of CHQ in various tissues (Gustafsson et al., 1983), which 
subsequently interferes with a number of physiological functions including glucose 
homeostasis and renal functions. However, the exploitation of alternative novel CHQ 
delivery routes could eliminate the inconvenient dosing schedule associated with the oral 
route by providing sustained controlled CHQ release over a long period of time and therefore 
avoiding high repetitive doses. Later sections will discuss the transdermal drug delivery as an 
alternative CHQ route of administration to oral delivery.   
 
1.4.3 Chloroquine absorption, metabolism and excretion 
 
CHQ is slowly eliminated from the body and hence accumulates in certain organs and tissues 
of the body. Following oral administration, maximum plasma concentrations of CHQ are 
attained within1-4 hours, indicating the drug’s rapid absorption (Gustafsson et al., 1983). 
About 70% of the administered dose of CHQ is excreted unchanged in the urine and the 
parent drug can still be detected in the urine for up to 120 days following a single 300 mg 
dose in humans (Pussard & Verdier, 1994). The high tissue affinity of CHQ is supported by 




infusion of the drug (Gustafsson et al., 1983).  After administration CHQ is swiftly 
dealkylated through cytochrome P450 enzymes (CYP) into the pharmacologically active 
mono-desethylchloroquine and bisdesethylchloroquine (Pussard & Verdier, 1994, Durcharme 
& Farinotti, 1996). Mono-desethylCHQ is the main metabolite of CHQ and has been shown 
to possess anti-malarial activity against CHQ-susceptible P. falciparum as the parent 
compound (Aderounmu, 1984). The ability of CHQ to bind and accumulate in various tissues 
following oral administration is thought to be one of the main factors responsible for the 
reported CHQ-induced disturbances in blood glucose homeostasis and impaired renal 
electrolytes handling. Therefore, there is a need of novel CHQ delivery routes, such as 
transdermal drug delivery systems, which will avoid the transiently high plasma CHQ 
concentrations observed following oral CHQ administration. In addition, the pathological 
effects of malaria on these parameters are unclear. Currently, there is no literature evidence 
that distinguishes the pathophysiological effects of malaria from that of CHQ in malaria 
patients. The next section discusses the some of the speculated pathophysiological effects of 
malaria and oral CHQ on glucose homeostasis, renal function. 
 
1.5 Adverse effects of CHQ or malaria parasites  
 
In the unprotonated form, CHQ is relatively lipophilic and is therefore absorbed and accumulated 
in cell plasma membranes prior to cell entry (Mellman, 1986).  Chloroquine accumulates in 
vacuoles, causing the neutralization of protons. The neutralization of these protons by CHQ 
results to in an increase in vacuolar pH (Poole & Ohkuma, 1981). Increase in intra-vacuolar pH is 
associated with the disruption of vacuole associated physiological processes, including the 
deactivation enzymes such as nucleases, proteases, glycosidases, lipases and phosphatases (Lenz 
& Holzer, 1984). The transiently high plasma CHQ concentrations following oral administration 
are associated with the accumulation of this drug in various organs including the kidneys, liver 
and heart where the drug elicits adverse effects  such as impaired kidney function and impaired 
glucose homeostasis. However, it is unclear whether these adverse effects are solely due to CHQ 
or whether the malaria parasite also exerts pathophysiological effects on these systems. At 
present, no studies have been done to distinguish between the pathophysiological effects of CHQ 
and malaria on blood glucose and renal function. The next sections will discuss some of the 






1.5.1 Effects of malaria on glucose homeostasis 
Hypoglycaemia has been reported in tropical malaria patients (Jarzyna et al., 2001). Multiple 
mechanisms through which the malaria parasites may precipitate hypoglycaemia in malaria 
patients have been proposed; including the inhibition of gluconeogenesis and anaerobic 
glycolysis (White et al., 1987, Taylor et al., 1988). The utilization of the host’s glucose stores 
by the malaria parasites is another factor that is believed to contribute to hypoglycaemia 
(White et al., 1983). Due to the high demand of glucose by the parasites, there is an increase 
exhaustion of the host’s hepatic glycogen stores to meet these demands, resulting  reduced 
blood glucose levels (White et al., 1983). However, there are no studies which have been 
conducted to support these proposed theories. Hence the current study investigated the effect 
of the Plasmodium parasite on blood glucose homeostasis to try and establish the mechanism 
for the reported hypoglycaemia in malaria patients.  
  
 
1.5.2 Effects of CHQ on glucose homeostasis 
 
Chloroquine has been reported to cause hypoglycaemia following oral administration 
(Jarzyna et al., 2001). Numerous studies suggest that CHQ may induce hypoglycaemia 
through multiple unclear mechanisms. Some literature evidence suggests that the CHQ-
induced hypoglycaemia is mediated through increased insulin secretion (Davis, 1997) or 
decreased insulin degradation (Knutson et al., 1985). Chloroquine is a diprotic base and is 
rapidly accumulated in acidic lysosomes and endosomes thereby elevating lysosomal pH. 
This increase in lysosomal pH compromises the optimal activity of lysosomal hydrolases that 
are responsible for the degradation of insulin, causing an increase in plasma  insulin 
concentration (Knutson et al., 1985). Jarzyna and colleague (1997) reported the inhibition of 
enzymes that are involved in gluconeogenesis following oral CHQ administration. These 
enzymes include glutamate dehydrogenase, a key enzyme in amino acid metabolism in the 
liver and kidney (Jarzyna et al., 1997, Jarzyna et al., 2001). The inhibition of this enzyme in 
turn results in a decrease in hepatic glucose output, which precipitate hypoglycaemia.  The 
accumulation of CHQ in the liver following oral administration has been reported to cause 
hepatocellular damage. This accumulation is associated with a decreased pyruvate transport 
into the mitochondria as well as the inhibition of glucose-6-phosphatase, which is required 




changes in blood glucose levels in malaria patients is caused by the parasite or oral 
administration of CHQ . Accordingly, the present study investigated the pathophysiological 
effects of malaria and CHQ on blood glucose to try and establish the main cause of the 
reported changes in blood glucose homeostasis.   
 
1.5.3 Effects of malaria on renal function 
Mild hyponatraemia, hyperkalaemia and acidosis have been reported in patients with 
complicated P. falciparum malaria (Etim et al., 2011). The reported hyperkalaemia is 
speculated to be linked to the increased acidosis that is associated with increased protein 





 are involved in renal tubule sodium exchange at the expense of potassium (K
+
) 
ions, resulting into increase potassium retention (Etim et al., 2011).  The increased release of 
K
+
 from RBCs during haemolysis is also thought to increase plasma K
+
 concentrations, 
resulting into hyperkalaemia. Constriction of renal vascular bed as well as splachnic blood 
vessels has been reported in malaria associated renal failure (Das, 2008.). This constriction of 
renal vascular bed more often than not leads to renal ischaenia. This ischaemia causes a 
reduction in urine volume, GFR and urinary sodium excretion (Elsheikha & Sheashaa, 2007, 
Das, 2008.). Parasitized red cells are sticky and tend to adhere to adjacent unparasitized 
erythrocytes and the capillary endothelium. This in turn, results in the formation of 
intravascular clumps that  impede the renal microcirculation of internal organs (Elsheikha & 
Sheashaa, 2007, Das, 2008.). 
 
1.5.4 Effects of CHQ on renal function 
Current evidence suggests that CHQ may influence kidney function when administered 
acutely or chronically in rats (Musabayane et al., 1993). High plasma CHQ concentrations 
have been observed  1-4 hour following administration of the drug (Gustafsson et al., 1983). 
About 51% of this CHQ is cleared by the kidney unchanged (McChesney et al., 1966). 
However, a small fraction of it accumulates in epithelia cells of the kidneys (Gustafsson et 
al., 1983). This deposition of CHQ in the kidneys is reported to alter kidney function. In 
addition, some of the administered CHQ is deposited in in the heart (Baguet & Fabre, 1999) 
where CHQ exerts antiarrythmic actions  to increase heart rate (Dondo & Mubagwa, 1990). 
The increase in heart rate is speculated to alter the perfusion pressure of the kidney, and 






) excretion without any changes in urine flow rate following acute 
intravenous CHQ administration (Musabayane et al., 1993). This increase in Na
+
 cannot be 
explained by changes in aldosterone, as no changes in this hormone were recorded. The 
mechanism for this natriuresis is thought to be attributed to CHQ induced increase in plasma 
AVP (Musabayane et al., 1993). Chronic administration of CHQ has been reported to cause 
renal Na
+
 retention possibly via increased plasma aldosterone concentration and reduced 
glomerular filtration rate (GFR) (Musabayane et al., 1994 , Musabayane et al., 2000b). The 
increased Na
+
 retention following chronic CHQ administration may also be accredited to the 
CHQ-induced changes in the kidney (Musabayane et al., 2000b) 
 
Chloroquine has been previously reported to increase  plasma the hormone, arginine 
vasopressin (AVP) following intravenous infusion.  This hormone plays an imperative role in 
water homeostasis within the body, and is thus vital for the regulation of blood pressure. The 
CHQ induced increase in plasma AVP is thought to be linked to the action of CHQ on the 
pathway through which AVP acts to increase membrane permeability of the renal 
tubules(Musabayane et al., 2000).  We have shown that orally administered CHQ inhibits the 
activation of adenylate cyclase (Musabayane et al., 2000). Adenylate cyclase is responsible 
for the activation of adenosine 3’, 5’ – cyclic monophosphate (cAMP). This monophosphate 
consequently phosphorylates aquaporin-2, resulting to the integration of aquaporins into the 
medullary collecting ducts and collecting tubules, ultimately causing an increase in water 
permeability (Boone & Deen, 2008). The inhibition of adenylate cyclase by oral CHQ results 
in reduced incorporation of aquaporins with no change in urine flow rate even though plasma 
AVP concentrations has been increased (Musabayane et al., 2000). The CHQ induced 
increase in AVP is believed to be mediated through pathways which involve nitric oxide. It is 
thought that oral administration of CHQ results in the activation of the enzyme, nitric oxide 
synthase within the kidney. In turn, NOS stimulates the secretion of AVP (Ahmed et al., 
2003). This AVP consequently causes an increase in Na
+
 excretion.   
 
Both oral and intravenous administrations of CHQ were associated with compromised renal 
function attributed to changes in renal hormones as well as kidney morphology. The current 
study will investigate the suitability of transdermal drug delivery route for the administration 
of CHQ. In addition it is unclear whether CHQ is the main cause of these changes in renal 




the study will investigate the effects of malaria alone on renal function and that of CHQ on 
renal function.  
 
1.6 Methods of drug delivery  
 
The conventional route for the administration of CHQ involves oral administration of tablets. 
In the past years this method of CHQ delivery has been successful in eradicating the malaria 
parasite during infection. However, oral administration of CHQ is associated with a number 
of disadvantages that have been previously described. When administered orally, CHQ has 
been shown to accumulate in epithelial cells of various tissues, such as the heart, kidney, 
spleen, adrenal glands and liver, disrupting their functioning. Due to the accumulation of 
CHQ in the circulation when administered orally, a number of vital organs such as the heart, 
kidney and liver, are negatively affected. This delivery system is also associated with an 
inconvenient dosing schedule. Hence the current study will investigate a novel CHQ delivery 
system, which will eliminate the inconvenient dosing schedule that is associated with oral 
administration and mask bitterness of CHQ. This new delivery method is also envisaged to 
minimize the toxicity of the drug observed in oral administration, by reducing the amount of 
deposition of the drug in various tissues. In our laboratory we are focusing on transdermal 
drug delivery system. We have previously shown that oral administration of amidated CHQ 
beads formulation is able to sustain control CHQ release into the blood stream (Munjeri et 
al., 1998). In addition, we have successfully delivered CHQ topically into the rat via the use 
of an amidated pectin hydrogel matrix patch as assessed by changes in renal Na
+
 changes 
(Musabayane et al., 2003).  However, plasma CHQ concentrations following transdermal 
CHQ administration has never been measured. Also, the effect of this pectin CHQ matrix 
patch on parasitaemia has not yet been demonstrated. Accordingly, this study will investigate 
the effects of transdermal delivery of CHQ on P. berghei infected rats, and evaluate plasma 
CHQ concentrations following transdermal application.  
 
1.6.1 Transdermal drug delivery  
 
Transdermal drug delivery (TDD) systems are topically administered drugs in the form of 
patches. These systems deliver drugs for systemic effects at a predetermined and controlled 
rate (Chien, 1992, Prausnitz & Langer, 2008). A number of drugs have been successfully 




number of advantages when compared to oral and intravenous administration. When 
administered orally drugs are susceptible to first pass degradation by the liver as well as 
gastrointestinal metabolism (Chien, 1992, Prausnitz & Langer, 2008). As a result of this 
degradation high drug concentrations are required for therapeutic effects (Prausnitz & 
Langer, 2008). In transdermal delivery system, there is no first pass metabolism by the liver 
since the drug is delivered directly into the systemic circulation. Since there is no first pass 
metabolism by the liver low drug concentrations are required. The great success of this 
system is lies in  its ability to provide a sustained controlled release (Musabayane et al., 
2003) and thus presenting  drug deposition in tissues. When compared to hypodermic 
injections, which are painful, generate dangerous waste and pose a risk of disease 
transmission by needle re-use (Prausnitz & Langer, 2008), transdermal delivery proves to be 
a better suited method for drug delivery. 
 
TDD proves to be a much more convenient route for the administration of CHQ. However, 
this system is limited by the skin outer layer, the stratum corneum.  The stratum corneum is 
physiologically responsible for the vital barrier function of the skin and does not allow drugs 
to spontaneously pass into the systemic circulation. The next section will discuss the 
composition of the stratum corneum as how it hinders drug transport into the systemic 
circulation for TDD systems.  
 
1.7 Physiology of the skin 
 
The skin is the largest organ of the human body and performs multiple vital functions which 
include forming a protective barrier against external chemicals, pathogens as well as 
preventing excessive body water loss. Skin is an important site of drug application for both 
local and systemic effects (Pathan & Setty, 2009). The skin is composed primarily of three 
structures, the epidermis which is the outermost layer, the dermis, and subcutaneous tissue 
(Kanitakis, 2002) .   
 
The epidermis is made up mainly of keratinocytes and dendritic cells (Kolarsick et al., 2011). 
However, keratinocytes form a large part of the epidermis. This outermost layer is commonly 
divided into four layers, the stratum germinativum, the stratum spinosum, the stratum 
granulosum and the stratum corneum (Murphy, 1997). Of all the various layers of the skin, 




corneum confers mechanical protection to the underlying epidermis and invasion by foreign 
substances by acting as  the main barrier for diffusion of the permeants (Jackson et al., 1993). 
This outermost layer of the skin is made up of 18-21 hexagonal cells, the corneocytes.  The 
corneocytes are rich in keratin and are scattered within crystalline lamellar lipid matrix to 
adopt a bricks and mortar arrangement (Elias, 1983). About 10% of this layer is made up of 
extracellular lipid. Literature evidence suggests that the barrier function of the skin is 
ascribed to the lamellar lipids that are synthesized in the granular layer. These lipids are 
successively organized into the lipid bilayer domains of the stratum corneum. The lipid 
domains of the stratum corneum are the ones that pose a challenge for transdermal drug 
delivery as they hinder spontaneous penetration of hydrophilic drugs. The transport of 
hydrophilic and charged molecules into the systemic circulation is hindered by the lipid-rich 
nature of the stratum corneum as well as the low water content (20%) (Mehta, 2004).  
 
The rate at which drugs are transported across the stratum corneum is not only determined by 
solubility of the drug, but is also directly proportional to the oil/water partition coefficient, 
drug concentration in the formulation vehicle as well as the surface area of the skin exposed 
(Mehta, 2004). Current evidence indicates that the thickness of the stratum corneum varies in 
different regions of the body and may affect drug transport.  The stratum corneum is thickest 
in the plantar and palmar regions and thinner in the postauricular, axillary, and scalp regions 
of the body (Mehta, 2004). Thus drug transport may be limited in the regions such as the 
plantar and palmar regions. In an effort to maximise drug flux for TDD systems, penetration 
enhancement methods have been investigated. The next section discusses various penetration 
enhancers including dimethyl sulphoxide (DMSO) which will be used in the present study to 
enhance the transdermal delivery of CHQ. 
 
1.8.Penetration enhancers  
 
Penetration enhancers refer to substances that aid the absorption of molecules/drugs through 
the skin. For a penetration enhancer to be considered ideal certain criteria which include 
pharmacological properties, inertness, non-toxicity, nonirritating, nonallergenic, 
compatibility with the drug , odourless, and good solvent properties must be met (Finnin & 
Morgan, 1999, Sinha & Kaur, 2000). The permeation of drugs through the skin can be 




for the purpose of this study we shall be focusing on some chemical penetration enhancers as 
well as their plausible mechanisms of action. 
 
1.8.1. Sulphoxides 
Dimethyl sulphoxide (DMSO) is the earliest and most potent penetration enhancer belonging 
to the category of sulphoxides. This permeation enhancer is a very strong aprotic solvent 
capable of hydrogen bonding with itself rather than water (Williams & Barry, 2012). 
Although DMSO is a good enhancer, this sulphoxide has concentration-dependant effects. At 
high concentrations, DMSO can cause erythema and wheals of the stratum corneum and may 
denature proteins (Williams & Barry, 2012).  This enhancer uses multiple, complex 
mechanisms to aid the permeation of drugs. DMSO alters the stratum corneum’s keratin from 
alpha-helical to β-sheet conformation (Barry, 2001, Williams & Barry, 2012). The 
physiochemical structure of DMSO allows for the interaction of this molecule with the head 
groups of the lipid bilayer. This DMSO-lipid bilayer interaction alters packing of the lipid 
bilayer. In addition, DMSO penetrates and translocates forming microcavities with the lipid 
bilayer which increase volume available for drug diffusion. 
 
Dimethylacetamide (DMAC) and dimethylformamide (DMF) are chemical enhancers which 
are chemically related to DMSO. Similar to DMSO, both DMAC and DMF have a wide 
range of penetration enhancing activities (Williams & Barry, 2012).  Like DMSO, DMF has 
been shown to cause irreversible changes to the stratum corneum at high concentrations 
(Williams & Barry, 2012). Another DMSO structural analogue that has been synthesized is 
decymethylsulphoxide (DCMS). This analogue has ability to act reversibly on the stratum 
corneum. However, like DMSO, DCMS has concentration dependent effects. Literature 
evidence indicates that DCMS is more potent in the permeation of hydrophilic permeant and 
is less effective at promoting transdermal delivery of lipophilic drugs (Barry, 2001, Williams 
& Barry, 2012). Hence DMSO remains a potent sulphoxide penetration enhancer. In the 
present study, DMSO was used in combination with an antioxidant, vitamin E, as a 








1.8.2. Fatty acids 
Numerous fatty acids have been used as permeation enhancers.  Scientific evidence has 
shown that unsaturated fatty acids are much more effective in permeating the skin when 
compared to saturated fatty acids (Chi et al., 1995). Oleic acid and sodium oleate are amongst 
many penetration enhancers classified under fatty acids. According to Williams and 
colleagues, fatty acids with unsaturated alkyl chain lengths of around C18 attached to a polar 
head group yield optimum enhancers (Williams & Barry, 2012). Oleic acid has been shown 
to enhance penetration of a number of drugs at very low concentrations (Sintov et al., 1999). 
This permeation enhancer aids skin permeation by interacting with and modifying the lipid 
domains of the stratum corneum. In addition to this, oleic acid has an ability to form pools 
and exist as a separate phase. These pools offer permeability defects within the lipid bilayer 
thus allowing for the permeation of hydrophilic drugs (Tanojo et al., 1997, Williams & Barry, 
2012).   
 
1.8.3. Antioxidants  
Antioxidants are another class of potent penetration enhancers. One of the commonly used 
antioxidant is vitamin E. Vitamin E intercalates within the lipid bilayer and distorts the gel 
phase lipids, decreasing the gel state of phospholipid membrane, causing permeation (Thiele 
& Ekanayake-Mudiyanselage, 2007). In addition to skin permeation enhancement, Vitamin E 
confers protection to the skin due to the antioxidative properties of this vitamin, preventing 
skin damage. Vitamin E has been previously used in our laboratory as an antioxidant for 
transdermal drug delivery to thwart physiological damage to the skin. This antioxidant will be 
used in the current study to enhance CHQ permeation and prevent skin damage.  
 
Transdermal drug delivery has many attractions, including increased patient compliance and 
avoidance of gastrointestinal disturbances and first-pass metabolism of the drug. The stratum 
corneum is one of the limiting factors for the use of transdermal delivery as an alternative to 
other conventional drug delivery routes. However, the development penetration enhancers 
have played a substantial role in improving transdermal drug delivery systems and their 
pharmaceutical use.  Both penetration enhancers and transdermal delivery polymers form a 
vast part of transdermal drug delivery systems. The next section will discuss transdermal 
polymers, focusing solely on pectin which will be used in the present study. Oral 




We, therefore, speculate that transdermal application of CHQ via the pectin CHQ patch will 
sustain controlled release of CHQ into the blood stream.  
 
1.9.Transdermal delivery polymers 
 
Polymers are the backbone of a transdermal drug delivery system and form a big part of these 
systems. The following section will focus on the chemistry of pectin as a transdermal drug 
delivery polymer. Pectin is a non-toxic, water soluble gel-forming polysaccharide that has 
been widely used in many transdermal delivery systems due to its virtuous gelling properties 
which will be discussed in details in the next section. 
 
1.9.1. Chemistry of pectin  
 
Pectin is a naturally occurring polysaccharide that has gained increasing application in 
pharmaceutical and biotechnology industries. This biopolymer has been used successfully for 
many years in the food and beverage industry as a gelling agent and a colloidal stabilizer 
(Sriamornsak, 2003).  Pectin is a methylated ester of polygalacturonic acid. This polymer is 
commercially extracted from citrus peels and apple pomace under mildly acidic conditions 
(Sriamornsak, 2006). The composition and structure of pectin are poorly understood. Pectin 
consists mainly of D-galacturonic acid (GalA) units  which are joined in chains by means of 
(1-4) glycosidic linkage. These uronic acids have carboxyl groups, some of which are 
naturally present as methyl esters and others which are commercially treated with ammonia 
to produce carboxamide groups.  In addition to the galacturonan segments, neutral sugars are 
also present. Rhamnose (Rha) is a minor component of the pectin backbone and introduces a 
kink into the straight chain and other neutral sugars such as arabinose, galactose and xylose 
occur as side chains (Oakenfull, 1991).  
 
The ability of pectins to form gels depends on the molecular size and degree of esterification 
(DE). The ratio of esterified GalA groups to total GalA groups is referred to as the DE. This 
DE ratio plays a major role in the classification of pectins (Sriamornsak, 2006). The 
polygalacturonic acid chain is partly esterified with methyl groups and the free acid groups 
may be partly or fully neutralised with sodium, potassium or ammonium (Sriamornsak, 
2003). The degree of esterification of pectin is dependent upon the species, tissue and the 




60-90% DE.   Two classes of pectin have been identified, the high methoxyl pectins and the 
low methoxyl pectins (LM). The low methoxy pectins can either be the conventionally 
demethylated or amidated molecules (Sriamornsak, 2003).  The DE values for high methoxyl 
generally range between 60-70%, and those of low methoxyl range between 20-40%. Both 
low methoxyl and high have different gelling mechanisms. High methoxylated pectin 
requires a pH within narrow range, that is, around 3.0 in order to form gels. In addition, high 
methoxylated pectin gels are thermally reversible and frequently contain a dispersion agent 
such as dextrose to prevent lumping (Sriamornsak, 2003). Low methoxylated pectin produce 
gels independent of sugar content, and are less sensitive to pH compared to high methoxyl 
pectin.  
 
The rate at which gelation of pectin takes place is affected by the degree of esterification, a 
higher DE causes more rapid setting. LM-pectins require the presence of divalent cations 
such as calcium for proper gel formation. The mechanism of LM-pectin gelation relies 
mainly on what is referred to as the ‘egg-box’ model (Grant, 1973) . This mechanism 
involves the formation of junction zones created by the ordered, side-by-side associations of 
galacturonans, whereby specific sequences of GalA monomer in parallel or adjacent chains 
are linked intermolecularly through electrostatic and ionic bonding of carboxyl groups. In 
addition, amidation increases or improves the gelling ability of low methoxy pectin. (May, 
1990), reported that amidated pectins require less calcium to gel and that this pectin is less 
susceptible to precipitation at high calcium concentrations. During gelation of amidated low 
methoxyl pectins, ionic interaction between galacturonic acid residues and hydrogen bonding 
between amidated galacturonic acid residues aid the gelation of the pectin (Sriamornsak, 
2002). These interactions result in the formation of a net-like cross-linked pectin molecule 
(Sriamornsak, 2002). The cross-linkages formed by ionic bonds between the carboxyls are 
also involved in the gelling of amidated pectins and form stronger bonds, producing a brittle, 
less elastic. This cross linking is of vital importance in the entrapping of drugs for TDD.  
 
The natural occurring polysaccharide, pectin, has a wide spectrum of pharmaceutical uses. 
These include cations poisoning prophylaxis, reduction of blood cholesterol levels and in 
diet(Wilson & Dietschy, 1974). In the current study, amidated pectin of lower DE will be 
used to provide a sustained controlled release of CHQ delivery into the systemic circulation 
and avoid gastrointestinal and hepatic degradation of CHQ. Both the ionic and hydrogen 




the addition of the divalent cation, calcium, increases the probability of the formation of 
cross-links with a given amount of calcium. 
 
1.10 Basis of the present study 
 
We speculated that use of pectin-CHQ matrix patch formulation may provide slow sustained 
release of therapeutic CHQ doses which clear the malaria parasites in the systemic 
circulation. We also envisaged that the sustained, slowly released CHQ concentration from 
the pectin-CHQ matrix patch will avert the avert the adverse effects oral CHQ on blood 
glucose homeostasis and renal fluid and electrolyte handling of P. berghei-infected rats  
 
1.11.Aims/ Objectives of the study 
 
1.11.1. Primary aim of the study 
 
The present study was designed to develop a novel CHQ-formulation that delivers sustained 
slow CHQ release into the systemic circulation. We also investigated the ability of this CHQ 
formulation to clear the malaria parasites in Plasmodium berghei-infected male Sprague-
Dawley rats. 
 
1.11.2. Secondary aims  
 
The secondary aims of the study were to: 
 Investigate the ability of the pectin CHQ matrix patch to sustain plasma CHQ 
concentrations  
 The other objective of the study was to investigate and distinguish between the patho-
physiological effects of malaria parasites and CHQ treatment on blood glucose 
homeostasis and renal fluid and electrolyte handling in rats. 
 Evaluate the effects of the transdermal delivery of CHQ on selected renal functions and 








MATERIALS AND METHODS 
2.1. Drugs and chemicals 
Drugs and chemicals were sourced as indicated: 
Amidated pectin (Herbstreith and Fox KG, Neuenburg, Germany); chloroquine diphosphate 
(C18H26CIN3∙2H3PO4), sigmacote, dimethyl sulphoxide (DMSO), Giemsa stain and May-
Grunwald solution (Sigma-Aldrich Chemical Company, St Louis, Missouri, USA); calcium 
chloride (CaCl2), potassium hydroxide (KOH), sodium sulphate (Na2SO4), sodium hydroxide 
(NaOH), potassium dihydrogen phosphate (KH2PO4) and 95% ethanol (C2H5OH) (Merck 
Chemicals (PTY) LTD, Johannesburg, South Africa); vitamin E (Pharma Natura (PTY) LTD, 
Johannesburg, South Africa); eucalyptus oil (Barrs Pharmaceutical Industries cc, Cape Town, 
South Africa); diethyl ether (C4H10O) (NT Laboratory Supplies (PTY) LTD, Johannesburg, 
South Africa); sulphuric acid (H2SO4) (BDH Chemicals LTD, Poole, Dorset, England), 





 (Abcam, Cambridge, Massachusetts, USA)
 
. All 
chemical reagents were of analytical grade. 
 
2.2. Animals 
Male Sprague-Dawley rats (90-120 g) bred and housed in the Biomedical Resource Unit of 
the University of KwaZulu-Natal, Westville campus were used in the study. The animals 
were maintained under standard laboratory conditions of constant temperature (22±2 °C), 
CO2 content of <5000 p.p.m., relative humidity of 55±5%, and illumination (12 h light/dark 
cycles) and the noise levels of <65 decibels. The animals had free access to standard rat chow 
(Meadows, Pietermaritzburg, South Africa) and water. 
 
2.3. Ethical consideration 
Ethical clearance was obtained from the University of KwaZulu-Natal’s Ethics committee 






2.4. Experimental design 
Short-term effects of transdermally applied pectin-formulations and oral CHQ treatment, on 
parasitaemia, blood glucose concentration and renal function were monitored in separate groups 





2.5.1. Preparation of pectin-CHQ matrix patches 
Low methoxyl amidated pectin with a degree of esterification (DE) of 23% and an amidation 
of 24% was used for the preparation of the CHQ patches.  This type of pectin has an ability to 
form gels independent of sugar content, and is less sensitive to pH compared to high 
methoxyl pectins. Pectin-CHQ hydrogel matrix patches were prepared using a protocol well-
established in our laboratory (Musabayane et al., 2003) with slight modifications. Patches 
were prepared by dissolving various amounts of CHQ (5g and 10g) and pectin (4.4g) in 
separate beakers containing 110 mL de-ionised water. The beakers were then placed in a 
water bath at 37
º
C and agitated at 38 x G using a mixer (Heidolph instruments GmbH & Co. 
KG, Schwabach, Germany) for 15 minutes. Following agitation, DMSO (3.3 mL) was added 
and mixed for 5 minutes. Subsequently, vitamin E (1.65 mL) and eucalyptus oil (1.65 mL) 
were added to the mixture.  Following 1½ h of further mixing and agitation an aliquot, of the 
mixture (11 mL) was transferred to a petri dish and frozen at -5
o
C for 18 hours. After 
freezing, a 2% CaCl2 solution (1.5mL) was added on top of the frozen pectin and then left to 
stand at room temperature (±25
o 
C) for 10 min to allow for cross linking. The patches were 
stored at 4
o
C until use. 
 
2.5.2. Determination of percentage CHQ incorporation  
 





dissolved in 100 mL of Sorensen buffer of pH 7.4 overnight. A volume of 2 mL of the final 
mixture was drawn for spectrophotometric analysis of CHQ (Ultraviolet Novaspec II 
spectrophotometer (Biochrom LTD, Cambridge, England). The blank contained CHQ-free 




2.6. Induction of malaria 
A CHQ susceptible strain of P. berghei was used for the induction of malaria. The P. berghei 
parasite was supplied by Professor Peter Smith (University of Cape Town, Division of Clinical 
Pharmacology, South Africa).This Plasmodium parasite is one of the four species of malaria 
parasites that infects murine rodents of West Africa (Cohuet et al., 2006). P. berghei has been 
used in many studies as an experimental model for malaria (Bagot et al., 2002, Goodman et al., 
2013). The P .berghei’s life cycle is similar to that of human infecting Plasmodium parasite, 
making P. berghei a good experimental model to study human malaria. Malaria was induced in 
male Sprague-Dawley rats via a single intra-peritoneal injection of P. berghei (10
5 
parasitized red 
blood cells). (Gumede et al., 2003). Successful malaria induction was confirmed by microscopic 
examination of Giemsa stained thin smears of the tail blood.  Percentage parasitaemia ranging 
from 15 - 20% was considered as a stable malaria state before commencing any experimental 
procedures. 
 
2.7. Effects of oral and transdermal CHQ treatments 
To evaluate the short-term effects of transdermally applied pectin-CHQ patch, a CHQ patch 
containing 56 mg was used. This dose was selected based on our preliminary studies.  
The studies carried out over a period of 3 weeks divided into pre-treatment (days 0-7), 
treatment (days 8-12) and post treatment (days 13-21) periods. To distinguish the effects of 
CHQ treatment and malaria infection on blood glucose concentration and renal function, 
separate groups of control and CHQ treated non-malaria and malaria infected rats were used. 
The animals were housed individually in Makrolon polycarbonate metabolic cages 
(Techniplasts, Labotec, South Africa) at the Biomedical Resource Unit, University of 
KwaZulu- Natal. 
The effects of oral CHQ treatment (30mg), twice daily, 8 hours apart and a once off topical 
application of the pectin CHQ matrix patch (28mg) were compared in non-infected and P. 
berghei-infected rats. These doses were calculated based on current clinical doses for the 
treatment of malaria. The orally treated group was given CHQ diphosphate solution (30mg) 
twice daily at 09h00 and 17h00 by means of a ball-tipped, 18-gauge gavage needle (Kyron 
Laboratories (Pty) LTD, Benrose, South Africa) attached to a 1 ml syringe, for 5 consecutive 




treated with pectin CHQ matrix patches containing various amounts of CHQ (28, 56 and112 
mg) respectively. On the first day of the treatment period, pectin CHQ matrix patches were 
applied at 9h00. Prior to treatment, the rats were shaved on their dorsal region for the 
application of the pectin CHQ matrix patch. The patch was secured in place with adhesive 
hydrofilm (BSN Medical, Pinetown, South Africa) (See Figure 2). Parasite density was 
monitored daily at 9h00, in all groups of animals by microscopic examination of Giemsa 






Figure 2: Transdermal application of the pectin-CHQ matrix patch on a shaved rat back 






2.7.1. Parasitaemia monitoring  
 
Rats were monitored for % parasitaemia from the day of infection and days of survival 
relative to the control. Parasitaemia was scored on Giemsa-stained tail-blood films. Briefly, 
a small incision at the tip of the rat tail was made followed by placing a small drop of blood 
on a microscope slide. The blood was smoothly and uniformly smeared using a second 
microscope slide. The blood film on the slide was air-dried, fixed in 90 % methanol for 30 
seconds and then stained in Giemsa stain for 20 minutes. Finally, the stained slide was air-
dried and viewed under a microscope (Olympus cooperation, Tokyo, Japan) with a x50–
x100 oil immersion objective (Olympus cooperation, Tokyo, Japan). Parasite density was 
calculated as a percentage of infected RBCs. This was achieved by counting the total 
number of red blood cells and the parasitized red blood cells in 5 microscope fields.   
 
% parasitaemia = Total parasite count x 100 
                             Total RBC count  
 
 
2.7.2. Effects of CHQ on blood glucose and physico-metabolic parameters 
Body weights, amounts of water, and food consumed were measured in control and treated 
animals at 09h00 every 3
rd
 day during the pre-treatment and post treatment periods, and daily 
during the treatment period. Blood glucose concentration was measured 6 hours after 
treatment in all groups of animals using blood glucose testing strips, (OneTouch select Test 





urea and creatinine were also measured (See section 2.9.2).  
 
2.7.3. Effects of CHQ on mean arterial pressure (MAP) 
Mean arterial pressure was monitored every third day at 09h00 during the pre-treatment and 
post-treatment periods. However, during the treatment period MAP was monitored daily in 
Sprague Dawley rats using the non-invasive tail cuff method (IITC Life Sciences Inc., 
Woodland Hills, California, USA) as previously described (Musabayane et al., 2007). The 
unit makes use of the IITC hardware system consisting of an automatic scanner pump, 




blood pressure of the tail vein of the animal is displayed on the computer screen. Prior to 
MAP measurement, the equipment was calibrated to eliminate any discrepancies.  The 
animals were warmed in an enclosed chamber (IITC Life Sciences Inc., Woodland Hills, 
California, USA) for 30 minutes at ±30°C before taking three blood pressure recordings of 
each animal (Gondwe et al., 2008). 
Haematocrit levels were also monitored in all groups of animals at 0900 every 3
rd
 day during 
the pre-treatment and post- treatment periods, and daily during the treatment period. Briefly, 
blood was collected into heparinised capillary tubes using the tail prick method. The sealed 
capillary tubes were then centrifuged for 3 minutes at 906 x G with a Micro-haematocrit 
centrifuge (346 MSE Centrifuge Manufacturer, London, UK). Haematocrit was determined 
by calculating the percentage of the total blood volume to packed cell volume. 
 
2.8. Terminal studies 
To assess the effects of CHQ treatments on some biochemical parameters, plasma CHQ 
profiles, electrolytes, AVP and insulin concentrations, separate groups of non-fasted 
conscious animals (n=6) were sacrificed during pre-treatment at days 0 and 7, treatment 
period at days 8, 9, 11, 12 and post-treatment period at day 21. The animals were 
anaesthetized by placing them in an anaesthetic chamber with 100 mg/kg of halothane for 3 
minutes. Blood samples were collected by cardiac puncture into pre cooled heparinised tubes 
and centrifuged for 15 minutes at 959 x G at 4 °C (Eppendorf International, Hamburg, 
Germany). The plasma samples were stored in a Bio Ultra freezer (Snijers Scientific, Tilburg, 







), urea, creatinine, CHQ, insulin and AVP. Kidneys were collected, weighed 
gravimetrically (Mettler balance PC 180-insruments, Protea Laboratory Services, South 
Africa) and snap frozen in liquid nitrogen, to assess the effects of both infection and CHQ 










2.9. Laboratory analysis 
 
2.9.1. CHQ concentration measurements  
Plasma CHQ concentrations were measured in separate groups of animals following 
treatment with either oral CHQ or pectin-CHQ matrix patch using a double extraction process 
as previously reported (Musabayane et al., 2000) with slight modifications. Prior to use, all 
glassware was coated with sigmacote to prevent the adhesion of CHQ to the glass surfaces. 
Plasma sample (0.2 mL) was added to a 250 mL volumetric flask, followed by 1 mL of 25% 
potassium hydroxide and 10 mL of diethyl ether. The solution was mixed for 1 minute and 
allowed to stand for 2 minutes at room temperature. A 1% solution of sulphuric acid (2 mL) 
was subsequently added to the mixture for acidification. Absorbance of resultant solution was 
read spectrophotometrically (Ultraviolet Novaspec II spectrophotometer (Biochrom LTD, 
Cambridge, England) against a CHQ-free plasma blank at 343 nm. The obtained absorbance 
values were extrapolated from the standard curve to determine plasma CHQ concentrations 
Prior to plasma CHQ measurements, a CHQ standard curve was constructed using various 
CHQ concentrations ranging between 1.5 – 50.0 µg/mL. These CHQ concentrations were 
freshly prepared and read at 343 nm using Ultraviolet Novaspec II spectrophotometer 
(Biochrom LTD, Cambridge, England) and absorbance values were used to construct the 
standard curve, which was subsequently used to extrapolate plasma CHQ concentrations in 
test samples 
 
2.9.2. Electrolytes measurements 






 and creatinine concentrations were determined by ion 
activity using the Beckman Coulter (Synchron LX20 Clinical Systems, Fullerton, Carlifornia, 
USA). Creatinine estimation employed the reaction of creatinine and picric acid at alkaline 
pH to form a yellow-orange complex, creatinine picrate. For the estimation of urea, the 
hydrolytic degradation of urea in the presence of the enzyme urease was used.  Standard kits 
and reagents purchased from Beckman Coulter, Dublin, Ireland were used for the analysis. 
Glomerular filtration rate (GFR) assessed by creatinine clearance (Ccr) was calculated using a 
standard formula [Ccr=Urine creatinine concentration x Urine flow rate (V) / Plasma 
creatinine concentration] based on the measurements of the plasma and urinary 





2.9.3. Hormone analysis  
2.9.3.1. Insulin assay 
Plasma insulin concentrations were measured using the ultra-sensitive rat insulin ELISA kit 
(DRG diagnostics EIA-2943 GmbH, Marburg, Germany). The kit consisted of a 96 well plate 
coated with mouse monoclonal anti-insulin, enzyme conjugate, standards, enzyme conjugate 
buffer, substrate 3,3',5,5'-tetramethylbenzidine (TMB), wash buffer and a stop solution. This 
assay is a solid phase two-site immunoassay based on the direct sandwich technique in which 
two monoclonal antibodies are directed towards separate antigenic determinants on the 
insulin molecule. During the incubation period insulin in the sample reacts with peroxidase-
conjugate anti-insulin antibodies bound to the microtitration well. The unbound enzyme 
labeled antibody was removed by the washing step, leaving the bound conjugate to react with 
TMB. The reaction was stopped by adding sulphuric acid to give a colorimetric endpoint 
which is read spectrophotometrically on a microplate reader (BMG Labtech GmbH, 
Ortenberg, Germany) at 450nm.  
 
Each determination was done in duplicate for standards and test samples. A 50µl of each 
insulin standard was added to anti-insulin wells. Plasma samples (50µl) were added to the 
remaining anti-insulin wells, this was followed by the addition of the enzyme conjugate to 
standard and plasma samples wells. The plates were incubated at room temperature on a plate 
shaker (Heidolph, Schwabach, Germany) for 2 hours. This was followed by multiple wash 
using a wash buffer (350µl). After the final wash, the plates were inverted against absorbant 
paper to remove all the liquid in the plates. The substrate, TMB was then added to all wells 
and incubated for 30 minutes.  The reaction was stopped by adding 50 µl of stop solution to 
all wells and mixing for 5 minutes. Absorbance was measured using Spectrostar Nano 
microplate reader (BMG Labtech GmbH, Ortenberg, Germany). A standard curve was 
constructed from the absorbance values of the known concentrations of the standards using 
the spline regression curve. Insulin concentrations of the unknown samples were extrapolated 
from the standard curve. The lower and upper limits of detection were 1.39 pmol/L and 960 
pmol/L, respectively. The intra-assay analytical coefficient of variation ranged from 4.4 to 







2.9.3.2. Arginine vasopressin (AVP) assay 
 
A standard enzymatic method was used to determine plasma AVP concentrations. The assays 
were performed on an Arg
8
-Vasopressin ELISA Kit, using reagents purchased from the 
manufacturer (Abcam, Cambridge, Massachusetts, USA). The lower and upper limits of 
detection were 4 pmol/L - 923 pmol/L, respectively. The intra assay analytical coefficient of 
variation ranged from 5.9 to 10.6% and the inter-assay coefficient variation from 6.0 to 8.5%. 
2.9.3.2.1. Principle of the assay 
The kit components included a 96 well plate coated goat antibodies , vasopressin conjugate, 
vasopressin antibody, assay buffer, wash buffer concentrate, vasopressin standards, p-
nitrophenyl phosphatesubstrate (pNpp) and a stop solution. The Arg8-Vasopressin ELISA Kit 
is a competitive immunoassay for the quantitative determination of vasopressin in samples. 
The assay uses a polyclonal antibody-vasopressin conjugate to bind covalently in a 
competitive manner with vasopressin in unknown samples. During the incubation period 
AVP in the sample reacts with phosphatase-conjugate anti-vasopressin antibodies and anti-
vasopressin antibodies bound to the microtitration well. The washing step removes unbound 
enzyme labeled antibody, leaving the bound conjugate which reacts with pNpp. This reaction 
is stopped by adding acid to give a colorimetric endpoint that is read spectrophotometrically 
on a microplate reader (BMG Labtech GmbH, Ortenberg, Germany) at 405 nm. 
 
2.9.3.2.2. AVP extraction 
 
Plasma samples were subjected to an extraction process prior to use. Briefly, 100 µL of 
plasma sample and 200 µL of ice cold acetone were added into the eppendorf tubes. The 
mixture was vortex and centrifuged at 12000 x G for 20 minutes. After centrifugation, the 
supernatant was collected into a glass tube. A volume of 500 µL of ice cold petroleum ether 
was added to the supernatant. The mixture was centrifuged at 10000 x G for 10 minutes to 
obtain the ether and aqueous layer. The remaining aqueous layer was transferred into new 
glass test tubes and dried under gas for 48 hours. After the drying, white crystals were 







2.9.3.2.3. Assay procedure 
 
Each determination was performed in duplicate for both standards and the test samples. The 
assay procedure was as follows: A volume of 100 µL of vasopressin standards (4, 10, 23, 59, 
148, 369 and 923 pmol/L) was added into anti-vasopressin wells. Samples (100 µL) were 
then added to the remaining wells followed by 50 µL vasopressin conjugate into all standard 
and sample wells. The plates were incubated at 4ºC for 24 hours. Following incubation, the 
reaction volume was emptied. 400µL of wash buffer was added to all wells and aspirated. 
The process was repeated 3 times. After the final wash, the plates were inverted firmly 
against absorbent paper to remove all the liquid. 200µL of substrate pNpp was added to all 
wells and incubated at 37ºC for 1 hour. The reaction was stopped by adding 50μL of stop 
solution to all wells and mixing on the shaker for 5 minutes.  The absorbance was read at 405 
nm using a Spectrostar Nano microplate reader (BMG Labtech GmbH, Ortenberg, Germany). 
A standard curve was constructed from the absorbance values of the known concentrations of 
the standards using the spline regression curve in Graph Pad Instat software (version 5.00). 
The respective AVP concentrations of the unknown samples were then extrapolated from the 
standard curve. 
 
2.10 Data analysis 
All data were expressed as means ± standard error of means (SEM). Data for untreated non-
infected and P. berghei infected rats were used as baseline. For chronic studies, the 
calculation of mean daily fluid voided and urinary amounts of electrolytes excreted, plasma 
insulin and AVP concentrations were used to assess renal function. GFR was evaluated by 
creatinine clearance as assessed by 24-hour urinary excretion rates of creatinine inrelation to 
plasma concentration. The MAP was presented graphically for the separate groups of 
animals. GraphPad InStat Software (version 5.00, GraphPad Software, San Diego, California, 
USA) was used for all statistical analyses. One way  analysis of variance (ANOVA) followed 
by Tukey-Kramer multiple comparison test was used to establish statistical comparison 









This chapter describes the following results:  
1) Percentage CHQ incorporation of the pectin patch  
 
2) Effects of oral and transdermal CHQ treatments on: 
i. Parasitaemia 
ii. Body weight, food and water intake 
  iii.  Glucose homeostasis  
  iv.  Renal function and  
   v.  Blood pressure 
 
3) CHQ pharmacokinetics 
  
3.1. CHQ incorporation in the pectin patch 
 
To determine the amount of CHQ loaded in the pectin hydrogel matrix formulation, 
dissolution studies were conducted on freshly prepared CHQ patches. The theoretical 
amounts of CHQ in the patches calculated based on the amount of CHQ added initially 
during patch preparation was considered 100%. 
Table 1: The total CHQ amounts in pectin CHQ patches with their corresponding percentage 
loading efficiencies (n=6 in each group) 
Area (mm
2
) Theoretical CHQ 
concentration in 
patch (mg/mL) 
CHQ concentration  
in patch (mg/mL) 
Percentage CHQ 
incorporation (%) 
4 ± 1 17 9  52 





3.2. Short-term studies 
The effects of twice daily oral administration of CHQ (30 mg) for 5 consecutive days and a 
once-off topically applied pectin-CHQ hydrogel formulation (56 mg) on parasitaemia, 
physical parameters, glucose homeostasis, renal function and blood pressure were evaluated 
in separate groups of non-infected and P.berghei-infected rats treated with a once-off topical 
application of the pectin-CHQ matrix patch. 
 
3.2.1. Effects on parasitaemia 
To assess the ability of the CHQ formulation to clear malaria parasites, the effects of a once-
off topical application of the pectin-CHQ patch (56 mg) and oral CHQ (30 mg) treatments on 
P. berghei-infected rats for 3 weeks were compared 
Following infection with P.berghei, percentage parasitaemia gradually increased reaching a 
peak of 55 ± 8% on day 12. Due to ethical reasons, the control animals were sacrificed on day 
12 of the experimental period. As such, all the subsequent results showing the infected 
control animals will no post treatment period (days 13-21).  
Oral CHQ treatment cleared the malaria parasites by day 7 as was indicated by a decrease in 
parasite density. The effects of treatment with the CHQ patch on blood parasite density in 
P.berghei-infected rats are shown in Figure 3; all residual parasites were cleared from the 
systemic circulation during the post-treatment period. Similar results were obtained in 
animals treated twice daily with oral CHQ.   
Figure 4 shows the effects of CHQ treatments on P. berghei-infected rats. Animals treated 
with oral CHQ twice daily for 5 consecutive days showed a significant reduction in 
percentage parasitaemia by day 12 from 29.33 ± 1.43% to 1.02 ± 0.25%, while the once-off 
transdermal application of the CHQ patch (28 mg) reduced and cleared the malaria parasite 
by day 20 of the experimental period. Interestingly, the once-off topical application of the 
CHQ patch containing 56 mg CHQ significantly reduced the parasitaemia from 38.72 ± 1.25 

















Figure 3: Parasite density in P.berghei-infected animals following a once-off topical 
application of the pectin-CHQ patch (56 mg) during the pre-treatment, treatment and post-
treatment periods (Magnification, 100 x10). (Leica SCN 400, Leica Microsystems CMS 














































Figure 4: Comparison of the effects of twice daily oral CHQ (30 mg oral) and once-off patch 
(28 and 56) treatments on percentage parasitaemia in P.berghei-infected rats with untreated 
animals (I control). Values are presented as means and vertical bars indicate SEM (n=6 in 










3.2.2. Studies on physico-metabolic parameters 
Body weight, food and water intake were monitored in non-infected and P.berghei-infected 
rats treated with either CHQ (30 mg, p.o) twice daily or a once-off topical application of the 
pectin-CHQ matrix patch (56 mg) to distinguish between the effects of oral and transdermal 
CHQ treatments on these parameters. 
 
3.2.2.1. Body weight, food and water intake 
 
Table 3 compares the effects of oral and transdermal CHQ treatments on mean body weight 
changes, food and water intake in separate groups of non-infected and P. berghei-infected 
rats. Untreated non-infected and P. berghei-infected rats served as non-infected (NIC) and 
infected controls (IC) respectively.  
 
 Untreated non-infected control animals progressively gained weight throughout the 
experimental period (Table 2). Oral administration of CHQ twice daily, for 5 consecutive 
days significantly decreased the mean body weight of non-infected rats by comparison with 
untreated non-infected rats.  In addition to decreased mean body weight, the food and water 
intake was significantly reduced in these animals. Interestingly, non-infected rats treated with 
topically applied CHQ via the pectin-CHQ matrix patch progressively gained weight exhibiting 
mean values comparable to those of untreated non-infected control animals. However, the 
food and water intake were not altered by the pectin-CHQ patch application (Table 2).  
 
The mean body weight of untreated P. berghei-infected rats significantly decreased by 
comparison with non-infected control rats throughout the 3-week study (Table 2). P. berghei-
infected rats treated with oral CHQ twice daily exhibited significantly decreased mean body 
weights. In addition to the reduction in mean body weights, P.berghei-infected rats presented 
significantly (p<0.05) reduced food and water intake during the treatment period. However, 
the once-off topical application of the pectin-CHQ matrix patch significantly (p<0.05) 
increased the mean body weight of P. berghei-infected rats to values comparable to those of 
untreated non-infected control rats (Table 2). Furthermore, the total food and water intake of 





Table 2: Comparison of the effects of twice daily oral CHQ (30 mg) treatment with a once-
off topically application of the pectin CHQ matrix patch (56 mg) on body weight changes 
food and water intake in non-infected and P. berghei- infected animals. Values are presented 
as means ± SEM, where columns represent means (n=6 in each group)  
p<0.05 by comparison to the non-infected control. # p<0.05 by comparison with oral CHQ 
treated animals 
 
Parameter Protocol Baseline Treatment Post-
treatment 
 
Food intake  
(g/100g)  
Control Non-infected 9 ± 1 10 ± 4 9 ± 1 
P. berghei -
infected 
10 ± 1 7 ± 2  N/A 
Oral Non-infected 9 ± 1 7 ± 1 9± 2 
P. berghei -
infected 
8 ± 1  6 ± 1 8 ± 3 
Patch Non-infected 10 ± 1 9 ± 1
#
  9 ± 1 
P. berghei -
infected 
9 ± 1 8 ± 2
#




Control Non-infected 15± 2 13 ± 1 15 ± 2 
P. berghei -
infected 
8 ± 3 10 ± 2 N/A 
Oral Non-infected 10 ± 1 10 ± 1 14 ± 1 
P. berghei -
infected 
8 ± 2 7± 2 12 ± 2 
Patch Non-infected 15 ± 1 14 ± 1
#
 14 ± 3 
P. berghei -
infected 
13 ± 1 13 ± 2
#
 15 ± 2 
 
% b.wt change  Control Non-infected 8±1 13 ±1 18 ±1 
P. berghei-
infected 
-6±2 -4±2 N/A 
Oral Non-infected 7±1 -2 ± 1 8 ± 1 
P. berghei 
infected 
-8±1 -7±1 -1± 1 















3.2.2.2. Effects on blood glucose concentrations 
Blood glucose concentrations were monitored in separate groups non-infected and P.berghei-
infected rats treated with either CHQ (30 mg, p.o) twice daily or a once-off topical 
application of the pectin-CHQ matrix patch (56 mg) to distinguish between the effects of oral 
and transdermal CHQ treatments. 
 
The blood glucose concentrations of untreated non-infected control animals ranged from 5.95 
± 0.17 to 6.80 ± 0.24 mmol/L throughout the experimental period. Oral administration of 
CHQ to non-infected animals significantly (p<0.05) decreased blood glucose concentrations 
to a value of 3.03 ± 0.19 mmol/L (Figure 5). Interestingly, the once-off topical application of 
the pectin-CHQ patch did not alter the blood glucose concentrations of non-infected animals 
by comparison with untreated non-infected animals (Figure 6).  
 
Untreated P. berghei-infected rats exhibited significantly reduced blood glucose 
concentrations by comparison to non-infected control animals. The administration of CHQ 
orally further reduced blood glucose concentrations of P. berghei-infected rats from day 8 to 
12 of the experimental period by comparison to untreated infected control at the 
corresponding time period (Figure 5). Interestingly, the once-off topical application of the 
pectin-CHQ matrix patch significantly (p<0.05) increased blood glucose concentrations of P. 
berghei-infected animals from 9 to day12 reaching a mean value of 6.07 ± 0.14 mmol/L by 

















































































Figure 5: Blood glucose concentrations profiles of untreated non-infected (A), oral CHQ (30 
mg, p.o) treated non-infected (B) (NI Oral) and P. berghei-infected rats (C) (I Oral). Values 
are presented as mean ± S.E.M, where columns represent means and vertical bars represent 
SEM (n=6 in each group). p<0.05 by comparison to non-infected control (NIC) and 


















































Figure 6: Blood glucose concentration profiles of non-infected (A) and P. berghei infected 
rats (B) treated with a pectin-CHQ matrix patch. Values are presented as mean ± S.E.M, 
where columns represent means and vertical bars represent SEM (n=6 in each group). 






3.2.2.3. Effects on plasma insulin concentrations 
To elucidate the mechanisms responsible for the CHQ-induced hypoglycaemia, blood was 
collected from separate groups of non-infected and P.berghei-infected rats treated with either 
CHQ (30 mg, p.o) twice daily or a once-off topical application of the pectin-CHQ matrix 
patch (56 mg). Plasma insulin concentrations were measured from samples collected on day 7 
of the pre-treatment period and day 8, 12 of the treatment period. 
The plasma insulin concentrations of untreated non-infected rats remained unaltered 
throughout the study. Both oral CHQ administration and a once-off topical application of the 
pectin-CHQ patch significantly (p<0.05) increased the plasma insulin concentrations of non-
infected animals by comparison with respective baseline values (Table 3).     
There were no changes in plasma insulin concentrations of untreated P.berghei-infected 
control animals throughout the 3-week study. During the treatment (day 8-12) and post-
treatment (day 21) periods, oral CHQ significantly (p<0.05) increased the plasma insulin 
concentrations of P.berghei-infected by comparison with baseline. Interestingly, following a 
once-off topical application of the pectin-CHQ patch, plasma insulin concentrations of P. 














Table 3: Comparison of CHQ, insulin and blood glucose concentrations in P. berghei-
infected rats treated with either twice daily oral CHQ (30 mg) or a once-off topical 
application of the pectin CHQ matrix patch (56 mg) (n=6 in each group). Values are 
presented as means ± SEM  





Treatment    Time 
(days) 
[CHQ] µg/mL Insulin pmol/L Blood glucose 
mmol/L  
 
Oral CHQ  
Non-infected 
 





583 ± 24 
 
289 ± 28 
 
28 ± 7 
39 ± 4 
5.98 ± 0.25 
3.03 ± 0.19 
Post-treatment 21 243± 59 13 ± 2 5.32 ± 0.13 





574 ±  47 
386 ± 32 
39 ± 4
 
29 ± 7 
3.72 ± 0.20 
2.29 ± 0.13 












468 ± 18 
 













Post-treatment 21 279 ± 12 12 ± 1
# 
6.53 ± 0.21 


























3.2.3. Renal function studies 
3.2.3.1. Effects on fluid, electrolyte handling and MAP  
 
3.2.3.1.1. Non-infected groups 
 







outputs of control non-infected rats throughout the 21 day experimental period. Oral 




 outputs from day 8 to day 12 of the experimental period, but the urinary Cl
-
 output 
was not altered. Interestingly, the treatment of non-infected animals with a once-off topical 
application of the pectin-CHQ matrix patch (56 mg) had no significant effect on the 24 hour 






 (Figure 11) 
The MAP and haematocrit of untreated non-infected rats did not change throughout the 3-
week study (Figure 9). However, oral administration of CHQ significantly (p<0.05) reduced 
both the MAP and haematocrit values of non-infected rats from 8 to day 12 by comparison 
with the untreated non-infected control animals (Figure 9).  Interestingly, a once-off topical 
application of the pectin-CHQ matrix patch had no significant effect on the MAP and 
haematocrit values of non-infected animals (Figure 13) 
 
3.2.3.1.1. P. berghei-infected groups 
 




outputs of untreated P. berghei-infected rats 
remained unchanged throughout the study. However, a significant increase in K
+
 output was 





 outputs at corresponding time periods (Figure 8), but the urine 
volume voided was reduced (Figure 10). Following a once-off topical application of the 
pectin-CHQ patch the mean K
+
 output of P. berghei-infected rats was comparable to that of 
the untreated infected control animals, although the mean daily urine volume (Figure 12), 
urinary Na
+





Following infection with P. berghei, a significant (p<0.05) reduction in MAP and 
haematocrit values was observed in untreated control animals from day 3 to day 12 of the 
experimental period. This reduction in MAP and haematocrit values was exacerbated oral 
administration of CHQ, which significantly reduced both MAP and haematocrit from day 8 to 
day 12 by comparison with untreated infected control animals (Figure 10).  Interestingly the 
MAP of P. berghei-infected animals treated with a once-off topically applied CHQ patch was 
not altered throughout the experimental period.  However, a significant increase in 
haematocrit values was observed following treatment with the pectin-CHQ matrix patch from 
day 9 to day 21 of the experimental period (Figure 14). 
 
In summary, oral administration of CHQ significantly reduced the MAP and haematocrit 
levels of non-infected and P. berghei-infected rats, while the pectin-CHQ patch maintains 


































































































 (B) and Cl
-  
(C) outputs in 
untreated non-infected (NIC) rats with oral CHQ (NI Oral) treated rats. Values are presented 
as mean ±SEM, where columns represent means (n=6 in each group). p<0.05 by 




























































































 (B) and Cl
-  
(C) outputs in 
untreated P. berghei infected (IC) rats with oral CHQ (I Oral) treated rats. Values are 
presented as mean ± SEM, where columns represent means (n=6 in each group). p<0.05 by 










































































untreated non-infected (NIC) rats with oral CHQ (NI Oral) treated rats. Values are presented 
as mean ± SEM, where columns represent means (n=6 in each group). p<0.05 by 




































































Figure 10: Comparison of the 24 hour urine output (A), MAP (B) and haematocrit
 
(C) in 
untreated P. berghei-infected (IC) rats with oral CHQ (I Oral) treated rats. Values are 
presented as mean ± SEM, where columns represent means (n=6 in each group). p<0.05 by 




















































































 (B) and Cl
-  
(C) outputs in 
untreated non-infected (NIC) rats with pectin-CHQ patch (NI Patch) treated rats. Values are 
presented as mean ± SEM, where columns represent means (n=6 in each group). p<0.05 by 
























































































 (B) and Cl
-  
(C) outputs in 
untreated P. berghei-infected (IC) rats with pectin-CHQ patch (I Patch) treated rats. Values 
are presented as mean ± SEM, where columns represent means (n=6 in each group). p<0.05 








































































untreated non-infected (NIC) rats with pectin-CHQ patch (NI Patch) treated rats. Values are 
presented as mean ± SEM, where columns represent means (n=6 in each group). p<0.05 by 





























































Figure 14: Comparison of the 24 hour urine output (A), MAP (B) and haematocrit
 
(C) in 
untreated P. berghei-infected (IC) rats with pectin-CHQ patch (I Patch) treated rats. Values 
are presented as mean ± SEM, where columns represent means (n=6 in each group). p<0.05 










 excreted during the treatment period 
The total amounts of fluid voided and electrolytes excreted in all groups during the treatment periods are 
summarized in Table 4. 
Oral administration of CHQ significantly elevated Na
+
 excretion in both non-infected and 
infected animals. In addition to natriuresis, the malaria parasite and oral CHQ induced 
hyperkalaemia in infected animals, while transdermal delivery of CHQ via the pectin-CHQ 
patch had no significant effects on renal fluid and electrolyte handling (Table 4). 
Table 4: Comparison of total amounts of urine volume, Na+, K+ and Cl
-
 excreted during the 
treatment period by non-infected and P.berghei-infected rats treated with either oral or 
transdermally delivered  CHQ with respective control animals (n = 6 in all groups). Data are 
expressed as means ± SEM (n = 6 in each group).  
 
 p<0.05 by comparison with the peak plasma CHQ concentration, # by comparison with 
oral CHQ treatment, ∞ by comparison with non-infected control.  
 
Parameter  NIC NI Oral NI Patch 










GFR (ml/min )  
8± 1 
18 ± 2 
56 ± 3 
23 ± 1 
0.9± 0.2 







30 ± 2 








25 ± 2 
0.9 ± 0.1 
 IC  I Oral I Patch 




















34 ± 2 
0.8 ± 0.3 







34 ± 2 
0.9 ± 2 







33 ± 2 




Table 5: Plasma biochemical parameters of non-infected and P.berghei-infected rats treated 
twice daily with oral CHQ for 5 consecutive days or a once-off topical application of the 
pectin-CHQ matrix patch (n = 6 in all groups)  
 
 p<0.05 by comparison with the peak plasma CHQ concentration, # by comparison with 









Non infected P. berghei 
infected 




Na+ (mmol/l) 134 ± 3 136 ± 4 140 ± 2 140 ± 41 138 ± 2 139 ± 4 
K+ (mmol/l) 5.89 ± 0.80 6.70 ± 0.36 4.33 ± 0.82 7.09 ± 0.33 5.36 ± 0.31 5.49 ± 0.44# 
Cl- (mmol/l) 102 ± 8 98 ± 8 102 ± 9 96 ± 7 103 ± 9 102 ± 9 
GFR (ml.min 100g-1) 0.80 ± 0.02 0.90 ± 0.01 0.90±0.02 0.90±0.02 0.80±0.01 1.10±0.02 
Kidney mass (g/100g 
b.wt) 
0.80 ± 0.02 0.89 ± 0.01 0.89 ± 0.03 0.83 ± 0.01 0.80 ± 0.02 0.83 ± 0.02 
 
Treatment Na+ (mmol/l) 131 ± 2 133 ± 4 134 ± 2 140 ± 4 
 
139 ± 1 141 ± 2 
K+ (mmol/l) 5.51 ± 0.30 4.50 ± 0.58 4.63 ± 0.40 10.50 ±1.56  5.56 ± 0.31 5.49 ± 0.40# 
Cl- (mmol/l) 104 ± 3 101 ± 3 103 ± 3 101 ± 2 98 ± 3 103 ± 3 
GFR (ml.min.100g-1) 0.91±0.03 0.83±0.02 0.80±0.02 0.90±0.01 0.90± 0.03 0.89±0.03 
Kidney mass 
(g/100g b.wt) 




Na+ (mmol/l) 130 ± 3 N/A 131 ± 3 137 ± 4 147 ± 1 139 
K+ (mmol/l) 5.39 ± 0.10 N/A 3.73 ± 0.3 10.09± 4.06 4.37±0.79 4.37 ± 0.80# 
Cl- (mmol/l) 101 ± 1 N/A 101 ± 3 103 ± 2 102 ± 4 101 ± 2 
GFR(ml.min.100g-1) 0.90±0.01 N/A 1.02±0.03 1.0±0.01 1.2±0.02 1.30±0.03 
Kidney mass 
(g/100g b.wt) 




3.3. Laboratory analysis 
3.3.1. Plasma CHQ pharmacokinetics 
Transiently high plasma CHQ concentrations have been previously reported following oral 
CHQ  administration. Accordingly we evaluated and compared the effects of a once-off 
topical application of the pectin-CHQ patch (56 mg) treatment on plasma CHQ concentration 
to those of oral (30 mg, p.o) twice daily. Blood was collected  from separate groups of P. 
berghei-infected rats treated with either oral or pectin-CHQ patch during the treatment (day 
8-12) and post-treatment period (day 21). 
Table 6 shows plasma CHQ concentration profiles at different time intervals following oral 
CHQ treatment, twice daily, 8 hours apart and a once-off transdermal application of the 
pectin matrix patch. Significantly (p<0.05) high plasma CHQ concentrations were observed 
on day 1 of the treatment period in both orally and transdermally treated animals. However 
these high plasma CHQ concentrations were significantly (p<0.05) reduced by day 2 in 
animals treated with oral CHQ. During the post treatment period, plasma CHQ concentrations 
were significantly reduced in the oral CHQ treated group by comparison to the patch treated 
group. . The once-off topical application of the pectin-CHQ matrix patch treatment sustained 
plasma CHQ concentrations for 5 days as shown in table 6.  
Table 6: Plasma CHQ profiles of P. berghei-infected rats treated twice daily with oral CHQ 
(30mg) treatment and transdermally applied CHQ (56 mg). Values are presented as means ± 
SEM. (n=6 in each group)  
 Time (Days) CHQ concentration (µg/mL) 





8 583 ± 24  455 ± 28 
9 396 ± 24 410 ± 24 
11 487 ± 31 399 ± 24
 #
 
12 289 ± 28 365 ± 23
#
 
Post-treatment  21 188 ± 18 298 ± 18
#
 
 p<0.05 by comparison with the peak plasma CHQ concentration, # by comparison with 




3.3.2. Effects of CHQ treatments on plasma AVP 
 
To elucidate the possible mechanism responsible for the natriuretic effects of oral CHQ, 
plasma AVP concentrations were measured on samples collected from P. berghei-infected 
rats treated with either oral CHQ or the pectin-CHQ matrix patch. The samples were 
collected on day 1, day 4 of the treatment and day 21 of the post-treatment period.  Plasma 
samples that were collected on 7 of the pre-treatment period served as baseline.  
 Table 7 shows the effects of twice daily oral CHQ administration and a once-off topical 
application of the pectin-CHQ matrix patch on plasma AVP concentrations of P.berghei -
infected rats during the treatment and post-treatment periods. Oral CHQ treatment 
significantly (p < 0.05) increased plasma AVP during the treatment period by comparison to 
baseline samples collected on days 7 from untreated P. berghei-infected rats. A once-off 
topical application of the pectin-CHQ matrix patch had no significant effects on plasma AVP 
concentrations by comparison to baseline. 
Table 7: Comparison of plasma AVP concentrations in P. berghei-infected rats treated with 
either oral CHQ (30 mg) or CHQ patch (56 mg). Values are presented as means ± SEM, 
where columns represent means and vertical bars represent SEM (n=6 in each group)  
 Plasma AVP (pmol/L) 
 Oral CHQ Patch CHQ 
Baseline  481 ± 62 481 ± 62 
 




Post-treatment  535 ± 36 508 ± 34 
 












4.0. General  
 
The present study was primarily designed to develop a novel CHQ-formulation that delivers 
sustained slow CHQ release into the systemic circulation. We also investigated the ability of 
this CHQ formulation to clear the malaria parasites in Plasmodium berghei-infected male 
Sprague-Dawley rats. The other objective of the study was to investigate and distinguish 
between the patho-physiological effects of malaria parasites and CHQ treatment on blood 
glucose homeostasis and renal fluid and electrolyte handling in rats. A rodent infecting, CHQ 
susceptible P. berghei was used for the induction of malaria.  P. berghei widely used as an 
experimental model to study human infecting malaria is considered a safe model since this 
species of Plasmodium does not affect humans (Janse & Waters, 1995). Male Sprague 
Dawley rats (90-120) were used for the induction of malaria. These are growing rats and are 
highly susceptible to infection by the Plasmodium parasites. This makes these rats good 
experimental models since they are able to reach peak percentage parasitaemia which allowed 
for the investigation of the antimalarial activity of our novel CHQ-formulation. The results 
indicate that we were able develop a novel CHQ-formulation and achieved drug percentage 
incorporations ranging between 52-74%, these are the acceptable incorporations for 
transdermal drug delivery. Moreover, the mounts of CHQ obtained in the pectin-CHQ matrix 
patches equates to clinical doses. We have also demonstrated the ability of the pectin-CHQ 
matrix patch formulation to deliver sustained controlled therapeutic doses of CHQ which 
cleared the malaria parasites within a period of 5 days. Moreover the novel CHQ formulation 
not only clears the Plasmodium parasites, but sustains normal blood glucose concentrations 
and does not affect renal function of malaria infected animals. The current data suggests that 
transdermal CHQ delivery has the potential to ameliorate the pathophysiological effects that 
are associated with oral CHQ treatment and could provide an alternative method for the 









4.1. Effects of CHQ treatments on parasitaemia  
 
CHQ has been the mainstay therapy in the treatment of malaria in many tropics. The success 
of this anti-malarial drug is ascribed to the ability to inhibit the replication of the Plasmodium 
parasites, thus clearing the parasites from the systemic circulation (Zhang et al., 1999). Oral 
administration of CHQ, twice daily, 8 hours apart for 5 consecutive days, and a once-off 
topical application of the pectin-CHQ matrix patch containing 56 mg CHQ reduced and 
cleared the malaria parasites. However, the pectin-CHQ matrix patch cleared the malaria 
parasites within a period of 5 days whereas the oral administration of CHQ only cleared the 
parasites after 7 days of treatment. The pectin-CHQ patch containing 28 mg CHQ, only 
cleared the Plasmodium parasites from the systemic circulation after 11 days of patch 
application when compared to orally administered CHQ which cleared the parasite after 7 
days. This prolonged time period to clear the parasites by our pectin- CHQ matrix patch 
might be attributed to the fact that 28 mg CHQ was our lower CHQ dose.The ability of the 
once-off transdermal application of the pectin-CHQ patch to clear the malaria parasites 
within a period of five days provides for the first time, evidence of sustained, controlled 
release of CHQ from our transdermal formulation. The pectin-CHQ matrix patch was able to 
provide therapeutic concentrations at a sustained rate for up to 5 days.  The current data 
suggests transdermal CHQ formulation as a practical alternative to conventional oral CHQ 
for malaria chemoprophylaxis and treatment. 
 
 
4.2. Blood glucose homeostasis 
To evaluate the effects of CHQ treatment on blood glucose homeostasis and to further 
distinguish between the effects of malaria parasites and CHQ treatment, P. berghei-infected 
rats were treated with either oral CHQ or a once-off topical application of the pectin-CHQ 
matrix patch. In addition the current study investigated the effects of a novel CHQ-
formulation on blood glucose homeostasis in an effort to avert the adverse effects that are 
reported following oral administration of CHQ.   
 
Following infection of rats with P. berghei, a significant reduction in blood glucose 




by the malaria parasites which are mediated through various mechanisms (White et al., 1987, 
Krishna et al., 1999). These include the inhibition of gluconeogenesis and anaerobic 
glycolysis (White et al., 1987, Taylor et al., 1988). However, the utilization of the host’s 
glucose stores by the malaria parasites is thought to be one of the main factors which 
precipitates hypoglycaemia in malaria patients (White et al., 1983). The depletion of vital 
gluconeogenic substrates such as thiamine by the malaria parasite plays a major role in the 
reported malaria-associated hypoglycaemia (Krishna et al., 1999). In addition, the malaria 
parasite-induced hypoglycaemia has also been attributed to increased hepatocellular damage 
by the parasites (Dekker et al., 1997). During replication, the Plasmodium parasites, invade 
hepatic cells where the parasites undergo proliferation and morphological changes. This 
increased migration and replication is associated with hepatocellular damage (Dekker et al., 
1997). Since the liver plays a pivotal role in the breakdown of the activated insulin-receptor 
complex, hepatocellular damage may result in slow insulin receptor recycling, which in turn 
may precipitate hypoglycaemia in malaria infected rats (Onyesom & Agho, 2011). However, 
in the absence of histological studies, the current study cannot fully explain the mechanisms 
responsible for the observed reduction in blood glucose concentration by the malaria 
parasites.  
Treatment of non-infected rats with oral CHQ twice daily, significantly decreased blood 
glucose concentrations. These results are in agreement with previous studies which have 
reported blood glucose lowering effects of CHQ (Knutson et al., 1985, Davis, 1997, Jarzyna 
et al., 2001). Some studies have attributed the CHQ-induced hypoglycaemia to increased 
insulin secretion (Davis, 1997) or decreased insulin degradation (Knutson et al., 1985). 
Chloroquine is a diprotic base which rapidly accumulates in acidic lysosomes and endosomes 
thereby elevating lysosomal pH. This increase in lysosomal pH compromises the optimal 
activity of lysosomal hydrolases that are responsible for the degradation of insulin, causing an 
increase in plasma  insulin concentration (Knutson et al., 1985). Indeed, we have also 
demonstrated increased plasma CHQ insulin concentrations following treatment with oral 
CHQ (Table 2).  This increase in plasma CHQ concentrations might be responsible for this 
reduction in blood glucose concentrations. Furthermore, some authors have linked the CHQ-
induced hypoglycaemia to the inhibition of gluconeogenesis due to increased CHQ-
hepatocellular damage (Jarzyna et al., 2001). Jarzyna and colleagues (2001) reported the 
inhibition of enzymes that are involved in gluconeogenesis following oral CHQ 




acid metabolism in the liver and kidney (Jarzyna et al., 1997, Jarzyna et al., 2001). The 
inhibition of this enzyme in turn results in a decrease in hepatic glucose output, which 
precipitate hypoglycaemia. The current study has demonstrated independent blood glucose 
lowering effects of oral CHQ  
 
Blood glucose concentrations of P. berghei-infected rats treated with oral CHQ significantly 
decreased with a concomitant increase in plasma insulin concentrations. The current data 
indicates that oral CHQ-induced hypoglycaemia is in part mediated through increased plasma 
insulin concentrations. The data obtained in the current study indicate that both the malaria 
parasite and oral CHQ possess blood glucose lowering effects.   
Interestingly, a once-off topical application of the pectin-CHQ patch had no significant 
effects on blood glucose concentrations of non-infected rats. The ability of the pectin-CHQ 
patch to maintain blood glucose concentrations comparable to those of the non-infected 
controls indicates that our novel CHQ formulation is able to avert the reported adverse effects 
of oral CHQ treatment on blood glucose homeostasis. Treatment of P.berghei-infected rats 
with a once-off topical application of the pectin-CHQ patch increased blood glucose 
concentrations by comparison with oral CHQ treated animals. This increase in blood glucose 
can be attributed to the continuous, increased food intake by the growing weanling rats. 
Interestingly, there was a significant decrease in blood glucose concentrations in animals 
treated with oral CHQ. When administered orally, CHQ has a bitter and unpalatable taste. As 
a result, the food intake by the animals is reduced which subsequently leads to a decrease in 
blood glucose levesl. The use of the pectin-CHQ matrix patch probably masked the bitterness 
of the drug; as evidenced by increased food intake (Table 2) which in turn increased blood 
glucose concentrations and percentage body weight of the animals treated with the pectin-
CHQ matrix patch. The data presented in current study demonstrates that transdermal 
delivery of CHQ not only averts the adverse effects of oral CHQ on blood glucose 
homeostasis, but may also mask the bitter taste of CHQ. The shortfall of the study is that 
hepatic and muscle glycogen concentrations were not measured as this might be another 







4.3. Effects on renal function 
 
4.3.1. Renal effects of CHQ   
 
Renal function studies were designed to investigate whether topically applied CHQ via the 
pectin-CHQ matrix patch can avert the reported oral CHQ-induced adverse effects on renal 
fluid and electrolyte handling. Furthermore, the current study investigated the effects of both 
the Plasmodium parasite infection and CHQ treatment on renal function in an effort to 
distinguish between the effects of oral and transdermal CHQ treatments on renal function. 
Previous reports indicated that CHQ treatment impairs kidney function, resulting in 
inappropriate Na
+
 handling (Musabayane et al., 1993) and a reduction in blood pressure 
(Sofola et al., 1981, Musabayane et al., 1999). These changes are believed to be attributed to 
the increased deposition of CHQ in tissues such as the heart and kidney following treatment 
with either oral or intravenous CHQ (McChesney et al., 1976). Therefore, there is a need for 
a novel CHQ formulation which will minimize deposition of CHQ in these tissues. The 
results indicate that transdermal delivery of CHQ via the pectin-CHQ matrix patch has no 
effect on renal electrolyte handling and hence has the potential to maintain normal blood 
pressure in non-infected and P.berghei-infected rats.  These results are suggestive of the 
ability of the pectin-CHQ matrix patch to provide slow, sustained CHQ releases into the 
circulation, thereby avoiding drug dumping in the kidneys, which might alter renal function.    
 
Treatment of non-infected and P.berghei-infected rats with oral CHQ significantly increased 
the 24 hour urinary Na
+ 
output. Indeed these finding are consistent with previous studies 
which have reported increase sodium excretion following acute CHQ administration 
(Musabayane et al., 1993, Musabayane et al., 1996). This CHQ-induced natriuresis is thought 
to be mediated through increased plasma AVP concentrations (Musabayane et al., 1993). 
CHQ increased plasma AVP without affecting the 24 hour urine output. Indeed, we have also 
observed increased plasma AVP concentrations following treatment with oral CHQ. CHQ 
supresses the vasopressin-induced increase in cyclic adenosine monophosphate (cAMP) 
production in isolated inner medullary collecting ducts (Musabayane et al., 2000). This is 
suggestive of the ability of CHQ to interfere with the normal antidiuretic response to 




natriuretic effects are thought to be mediated through the action of AVP effects on V1 
receptors (Musabayane et al., 1997), where AVP exerts pressor effects causing an increase in 
Na
+
 excretion without changing the urine flow rate. However, in the current study we have 
reported a reduction in the 24 hour urine output following treatment with oral CHQ. We 
speculate that this phenomenon may also be attributed to the reduced water intake that was 
recorded in animals treated with oral CHQ. Following a once-off topical application of the 
pectin-CHQ matrix patch to non-infected and P. berghei-infected rats, the 24 hour urinary 
Na
+
 output was comparable to that of the untreated non-infected control. These results are 
suggestive of the ability of the transdermal route to avert the adverse effects on renal Na
+
 
handling. In summary, the current data suggests that the oral CHQ natrietic effects are in part 
mediated through increased plasma AVP concentrations.  
Urinary K
+
 outputs of both untreated and oral CHQ treated P. berghei-infected animals were 
significantly increased during the treatment period. This hyperkalaemia is thought to be 
mediated through to increased release of K
+
 from RBCs due to haemolysis. Indeed, the 
present study also recorded a concomitant reduction in haematocrit levels of these animals. 
This reduction in haematocrit values is suggestive of a decrease in the number of red blood 
cells due to haemolysis, therefore releasing K
+
 from ruptured red blood cells. These findings 
are indeed in agreement with previous studies which have reported increased plasma K
+
 
concentrations in malaria patients (Abdalla et al., 1980, Kain et al., 2001). Kain and 
colleagues reported increased plasma K
+
 in malaria patients infected with Plasmodium vivax 
treated with oral CHQ (Kain et al., 2001). Following a once-off topical application of the 
pectin-CHQ matrix patch, the 24 hour urinary K
+ 
outputs of P. berghei-infected was 
increased. This increase in K
+ 
concentration might be attributed to RBC haemolysis by the P. 
berghei parasite rather than the pectin-CHQ matrix patch treatment. During replication, the 
Plasmodium parasite invades red blood cells and undergoes differentiation which 
subsequently ruptures red blood cells, resulting to the reduction of red blood cells (Phillips et 
al., 1986, Phillips & Pasvol, 1992 ) and increased release of K
+
 . The presence of 
hyperkalaemia in non-infected, patch-treated animals provides supporting evidence that 
transdermally delivered CHQ does not increase urinary K
+. 
These results suggests that  the 
malaria parasite, rather than CHQ treatment, is responsible for the increased K
+
 output in 






4.3.2. Effects of CHQ treatments on blood pressure   
 
To distinguish between the effects of oral and transdermal CHQ treatments on MAP, non-
infected and P.berghei-infected rats were treated with either oral CHQ or a once-off topical 
application of the pectin-CHQ matrix patch. In addition the current study investigated the 
effects of a novel CHQ formulation on MAP in an effort to avert the adverse effects on blood 
pressure that are reported following oral administration of CHQ.  
 
The results of the present study demonstrate the hypotensive effects of the P. berghei 
parasites. This reduction in blood pressure is aggravated by the oral CHQ treatment. The 
blood pressure-lowering effects of the Plasmodium parasite are possibly mediated through 
relative bradycardia and peripheral dilation that occurs during malaria infection as a result of 
increased histamine production (Butler & Weber, 1973). These histamines possibly act on 
blood vessels where they cause vasodilation of peripheral blood vessels, resulting to a 
reduction in blood pressure (Farrell & David, 1988, Bethel et al., 1996, Anigbogu & 
Olubowale, 2002). The possible mechanisms that are responsible for oral-CHQ induced 
reduction in blood pressure were not elucidated in the present study. However, some authors 
have attributed the oral CHQ hypotensive effects  to the ability of the drug to decreased 
vascular resistance that is induced via the production of nitric oxide which is a potent 
vasodilator (Don-Michael & Aiwazzadeh, 1970). Indeed, we have previously reported a 
reduction in both blood pressure and GFR following treatment with oral CHQ (Musabayane 
et al., 1994 ). However, the current study did not record any changes in GFR. This 
discrepancy cannot be explained by the present study. Interestingly, the once-off topically 
applied pectin-CHQ matrix patch had no effect on MAP. The data presented in the current 
study suggests that the malaria parasites and CHQ treatment work synergistically to reduce 
blood pressure in P. berghein-infected rats treated with oral CHQ. The possible mechanisms 
responsible for the reduction in blood pressure were not investigated in the current study 
 
4.5. CHQ Pharmacokinetics  
Chloroquine is a drug with an unusual combination of pharmacokinetic properties including a 
large volume of distribution (Gustafsson et al., 1983) and a resulting long half-life,  such that 
after a single dose, a plasma half-life of 3-5 days has been found (McChesney et al., 1976, 




whether transdermal CHQ formulation is able to achieve peak plasma CHQ concentrations 
and to sustain these CHQ plasma concentrations for a longer period. Peak plasma CHQ 
concentrations were achieved within a period of 24 hours following oral CHQ treatment. 
These findings are in agreement with previous reports which have shown rapid CHQ 
absorption following oral CHQ administration of this drug (Gustafsson et al., 1983).  A 
decrease in plasma CHQ concentrations observed after 24 hour of the first oral CHQ 
administration may be attributed to the lysosomotropic properties of this anti-malarial drug. 
Chloroquine has been reported to bind and accumulation in various tissues, including the 
heart, liver kidneys and spleen (Gustafsson et al., 1983, Ursing et al., 2009). The detection of 
CHQ in plasma  21 days after the last day of dosing is indicative of this drug’s long half- life 
and its slow rate of elimination from the system (Gustafsson et al., 1983, Gustafsson et al., 
1987). The plasma CHQ concentrations were reduced by 3-folds during the post treatment 
period, suggestive of the ability of CHQ to bind avidly to almost all the different epithelial 
cells and body tissues following oral administration. 
 
The ability of the CHQ patch to attain peak CHQ concentrations comparable to that of orally 
administered CHQ validates the rapid delivery of drug into the systemic circulation via the 
transdermal route. The pectin-CHQ matrix patch formulation described in the current study 
sustains a prolonged release of CHQ up to 5 days. These findings are in agreement with 
previous reports which have shown the ability of transdermal drug delivery systems to 
provide sustained controlled release of drugs into the systemic circulation (Naik et al., 2000, 
Prausnitz & Langer, 2008). Transdermally delivered CHQ was able to deliver sustained, 
controlled therapeutic CHQ doses which were able to clear the malaria parasites within a 
period of 5 days. Indeed, we have previously reported the ability of the pectin CHQ matrix 
patch to provided sustained CHQ release (Musabayane et al., 2003). Furthermore, following 
treatment with oral CHQ (30 mg) twice daily, for 5 days; an average of approximately 300 
mg of CHQ was administered to the animals. However, with transdermal application of the 
pectin-CHQ matrix patch, only 56 mg of CHQ was administered throughout the treatment 
period.  The use of the pectin-CHQ matrix patch may alleviate the side-effects that are 
associated with CHQ dumping in vital tissues following oral administration of CHQ. The 
current study has demonstrated the feasibility of the use the pectin CHQ matrix patch for 







The results described in this study demonstrate that the novel transdermal CHQ-formulation 
is able to deliver therapeutic doses of CHQ into the systemic circulation in a sustained, 
controlled manner. Furthermore, the delivered doses were able to clear the P. berghei 
parasites within a period of 5 days following a once-off topical application of the pectin-CHQ 
patch.  With the current study, we were able to distinguish between the pathophysiological 
effects of the P. berghei parasites and those of the CHQ treatments. The current data 
demonstrates the independent-blood glucose lowering effects of the malaria parasites and 
CHQ treatments. The results show that oral CHQ-elicited blood glucose lowering effects in 
experimental animals are in part mediated via increased plasma insulin concentrations. 
Interestingly, a once-off topical application of the pectin-CHQ patch was able to circumvent 
these adverse effects and maintained normal blood glucose concentrations. Oral 
administration of CHQ significantly increased the urinary Na
+
 output and was associated with 
hyperkalaemia. The increased urinary Na
+
 output was in part mediated through increased 
plasma AVP following oral CHQ administration. The CHQ formulation was able to 
circumvent these effects and did not alter the renal fluid and electrolytes handling. In addition 
to natriuresis and hyperkalaemia, oral CHQ administration reduced the MAP of experimental 
animals. These hypotensive effects of oral CHQ are thought to be mediated through CHQ-
induced increased production of vasodilators such as nitric oxide. However, the present study 
did not elucidate the mechanisms that are responsible for the hypotensive effects of CHQ. 
The pectin-CHQ matrix patch did not produce any significant changes in MAP, suggestive of 
the ability of the CHQ formulation to deliver slow, sustained CHQ release.  
In summary, the results presented in this dissertation demonstrate that the transdermal CHQ 
formulation does not only clear the malaria parasites from the systemic circulation, but also 
circumvents the adverse effects that are usually associated with oral administration of CHQ 
on blood glucose and renal electrolyte handling.  
5.1. Shortfalls of the study   
The shortfall of the current study is that liver and muscle glycogen concentrations were not 
measured as this might be another mechanism involved in the reduction of blood glucose 




suggested as one of the mechanisms responsible for the parasite-induced hypoglycaemia. 
However, there were no histological studies that were done on the liver tissue to assess 
histological changes. This study has also established blood pressure lowering effects of both 
the malaria parasites and oral CHQ treatment. No studies were conducted to elucidate the 
possible mechanisms responsible for these hypotensive effects of oral CHQ. Another 
limitation of the study is that CHQ concentration in tissues such as the kidneys, liver, 
pancreas and heart, were not assessed. This is of importance since the oral CHQ-induced 
disturbances in blood glucose homeostasis and renal function are in part ascribed to increased 
deposition of CHQ in these tissues.   
 
5.2. Recommendations for future studies  
We have established that oral CHQ elicit adverse effects on blood glucose homeostasis and 
renal function. However, these effects were averted by transdermal delivery of CHQ via the 
pectin-CHQ patch. Future studies should, therefore, assess the deposition of CHQ in tissues 
such as the kidneys, liver and pancreas following oral or pectin-CHQ matrix patch 
treatments, as this might provide an explanation for the observed effects of oral CHQ. Future 
studies need also to investigate other possible mechanisms that are responsible for the 
reported blood glucose-lowering effects of oral CHQ. For instance studies which will 
measure both liver and muscle glycogen concentrations need to be conducted. We also need 
studies which will elucidate the possible mechanisms that are responsible for the decrease in 
blood pressure that was reported following oral CHQ treatment. In the present study we have 
reported decreased haematocrit levels in P. berghei-infected rats, haematocrit is a good 
marker for anaemia. Studies which will elucidate the possible mechanisms responsible for the 
reduction in haematocrit are required. For instance, measurements of hepcidin, a recently 
discovered peptide hormone, that plays a major role in iron regulation and is thought to play a 
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